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Mouse models of human breast cancer: evolution
or convolution?
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Transgenic Oncogenesis Group, Laboratory of Cell Regulation and
Carcinogenesis, National Cancer Institute, Bethesda, Maryland, USA
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The remarkable generation of scores of increasingly sophisticated
mouse models of mammary cancer over the past two decades has pro-
vided tremendous insights into molecular derangements that can lead
to cancer. The relationships of these models to human breast cancer,
however, remain problematic. Recent advances in genomic technolo-
gies offer significant opportunities to identify critical changes that
occur during cancer evolution and to distinguish in a complex and com-
prehensive manner the key similarities and differences between mouse
models and human cancer. Comparisons between mouse and human
tumors are being performed using comparative genomic hybridization,
gene expression profiling, and proteomic analyses. The appropriate use
of genetically engineered mouse models of mammary cancer in preclin-
ical studies remains an important challenge which may also be aided by
genomic technologies. Genomic approaches to cancer are generating
huge datasets that represent a complex system of underlying networks
of genetic interactions. Mouse models offer a tremendous opportunity
to identify such networks and how they relate to human cancer. The
challenge of the future remains to decipher these networks in order to
identify the genetic nodes of oncogenesis that may be important
targets for chemoprevention and therapy.
2
Estrogen receptor alpha-positive and negative
mouse mammary tumors through somatic
mutations of p53 in mammary carcinogenesis
S-CJ Lin1, K-F Lee2, AY Nikitin3, KM Bushnell4, SG Hilsenbeck5,
RD Cardiff6, A Li1, K-W Kang1, SA Frank7, W-H Lee4, EY-HP Lee1
1Department of Developmental and Cell Biology and Department of
Biological Chemistry, University of California, Irvine, California, USA;
2The Salk Institute for Biological Studies, La Jolla, California, USA;
3Department of Biomedical Sciences, Cornell University, Ithaca, New
York, USA 4Institute of Biotechnology, Department of Molecular
Medicine, University of Texas Health Science Center at San Antonio,
San Antonio, Texas, USA 5Department of Medicine and Department of
Molecular and Cellular Biology, Breast Center, Baylor College of
Medicine, Houston, Texas, USA; 6Center for Comparative Medicine,
University of California, Davis, California, USA; 7Department of
Ecology and Evolutionary Biology, University of California, Irvine,
California, USA
Breast Cancer Res 2003, 5(Suppl 1):2 (DOI 10.1186/bcr661)
Approximately 70% of human breast cancers are estrogen receptor
alpha (ERα)-positive, but the origins of ERα-positive and ERα-negative
tumors remain unclear. Most mouse models produce only ERα-nega-
tive tumors. In addition, these mouse tumors metastasize at a low rate
relative to human breast tumors. We report that somatic mutations of
p53 in mouse mammary epithelial cells lead to ERα-positive and ERα-
negative tumors. p53 inactivation in pre-pubertal/pubertal mice, but not
in adult mice, leads to the development of ERα-positive tumors, sug-
gesting that developmental stages influence the availability of ERα-pos-
itive tumor origin cells. These tumors have a high rate of metastasis that
is independent of tumor latency. An inverse relationship between the
number of targeted cells and median tumor latency was also observed.
The median tumor latency reaches a plateau when targeted cell
numbers exceed 20%, implying the existence of saturation kinetics for
breast carcinogenesis. Genetic alterations commonly observed in
human breast cancer including c-myc amplification and
Her2/Neu/erbB2 activation were seen in these mouse tumors. Since it
is feasible to isolate ERα-positive epithelial cells from normal mammary
glands and tumors, molecular mechanisms underlying ERα-positive
and ERα-negative mammary carcinogenesis can be systematically
addressed using this model.
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Mouse models for BRCA1-associated breast
cancer
R-H Wang, W Li, X Xu, C Deng
National Institutes of Health, Bethesda, Maryland, USA
Breast Cancer Res 2003, 5(Suppl 1):3 (DOI 10.1186/bcr662)
Breast tumor suppressor gene 1 (BRCA1) is a well-known transcrip-
tion regulator, mutations of which cause tumor formation in a tissue-
specific manner. In the past years, we have studied functions of Brca1
in mouse models carrying a number of different mutations. We showed
that impaired Brca1 function causes chromosome damages, failure of
the G2/M cell cycle checkpoint, and centrosome amplification, leading
to p53-dependent lethality. Our further analysis revealed that Brca1
also plays an important role in spindle checkpoint through regulating
Mad2. We showed that mice carrying a targeted disruption of Brca1 in
mammary epithelium developed mammary tumors at low frequency
after long latency and the tumorigenesis was significantly accelerated
in a p53+/– genetic background. Mammary tumors were highly diverse
in histopathology and displayed extensive genetic/molecular alter-
ations, including overexpression of ErbB2, c-myc, p27 and cyclin D1,
and downregulation of p16. The most noticeable change is expression
of estrogen receptor alpha (ERα). We showed that the absence of
Brca1 resulted in increased expression of ERα in epithelial cells at pre-
malignant stages and initiating tumors. However, expression of ERα
was diminished in tumors of more advanced stages. This observation
suggests that ERα-mediated signals are involved in tumorigenesis.
Finally, we provided evidence that BRCA1 affects the MAPK pathway
through interacting with estrogen/ERα signals, which may account for
tissue-specific tumorigenesis.
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The regulated growth and development of the mammary epithelium
depends on the interaction between the epithelial cells with the adja-
cent extracellular matrix. This interaction is primarily mediated through
the integrin receptor family. One of the primary signaling effectors on
the integrin class of receptors is the integrin-linked kinase (ILK). To
explore the importance of integrin coupled signaling pathways in
mammary tumor progression, we have used transgenic mouse models
to elucidate the role of the beta-1 integrin and ILK in mammary tumori-
genesis and metastasis. First, we demonstrated that mammary epithe-
lial expression of ILK is capable of inducing focal metastatic mammary
tumors. Interestingly these mammary tumors exhibited evidence of
epithelial mesenchymal transition. These observations provide direct
evidence that mammary epithelial-specific expression of ILK can result
in the direct induction of mammary tumors. To further explore the
importance of the beta-1 class of integrin receptors and ILK in
mammary tumorigenesis, we have generated mammary-specific knock-
outs of either beta-1 integrin or ILK using the Cre/LOXP recombination
approach. Preliminary analyses of the mammary ductal outgrowth in
these strains has revealed that a functional ILK is required for normal
mammary gland development whereas a functional beta-1 integrin
appears to be dispensable for normal mammary gland development.
Although beta-1integrin receptor function is not required for normal
mammary gland development, mammary-specific ablation of beta-1
results in dramatic inhibition of mammary tumors in transgenic mice
expressing the Polyomavirus middle T oncogene. Taken together, these
observations suggest that a functional beta-1 integrin receptor is
required for efficient mammary tumor progression.
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A cardinal feature of human cancers is the progressive selection and
outgrowth of cells that possess increasingly aggressive properties.
This process ultimately leads to resistance to therapeutic agents,
distant metastasis, and tumor recurrence. Together, these three mani-
festations of tumor progression are responsible for the vast majority of
cancer deaths. Nevertheless, while tumor progression constitutes a
problem of unrivaled clinical importance, the mechanisms underlying it
are largely unknown. As such, elucidating the molecular, cellular, and
pathophysiological events that contribute to tumor progression is a crit-
ical priority in cancer research. To better define the genetic, cellular,
molecular, and physiological events that contribute to breast cancer
progression, we have created a series of novel inducible bitransgenic
mouse models in which the oncogenes c-myc, Neu, Wnt1, v-Ha-Ras,
and Akt1 can be conditionally expressed in the mammary epithelia of
animals treated with tetracycline derivatives. Tumor formation in each of
these models is highly penetrant, mammary-specific, and absolutely
dependent on transgene induction by doxycycline. The properties of
this model system permit the direct visualization and analysis of each
stage of mammary tumorigenesis from normal mammary tissue in the
uninduced state to hyperplasias, atypical hyperplasias, invasive carci-
nomas, and distant metastases that arise as a consequence of onco-
gene activation. The inducible nature of the transgenic models that we
have developed permits essentially complete downregulation of an
oncogenic stimulus within an intact tumor. Remarkably, we have found
that—following transgene deinduction by doxycycline withdrawal—many
of these oncogene-induced primary mammary tumors rapidly regress to
a clinically undetectable state. However, despite this dramatic regres-
sion behavior, a substantial fraction of tumors that have previously
regressed to a non-palpable state recur spontaneously in the absence
of transgene expression over periods of up to 1 year. This finding sug-
gests that many animals in whom tumors have regressed still harbor
residual cancerous disease and that additional genetic events may
occur in these remaining cells that lead to the recurrence of actively
growing tumors. In addition, we have further demonstrated that a
subset of primary mammary tumors fail to regress fully following doxy-
cycline withdrawal, and instead acquire the ability to survive and grow
in the absence of oncogene overexpression. In some cases, this behav-
ior is associated with identifiable spontaneous genetic events that are
tightly linked to the ability of tumors to progress to transgene indepen-
dence. In aggregate, the tendency of mammary tumors in this system to
metastasize, to develop resistance to oncogene downregulation, and to
recur spontaneously with long latency suggests that these models
mimic critical aspects of the natural history of human breast cancer. As
such, this system may represent a valuable new means to understand
the biology of tumor progression and to identify the molecular mecha-
nisms by which mammary tumors escape their dependence on particu-
lar oncogenic pathways for growth.
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Genetic manipulation of the mammary gland by
transplantation
P Edwards
Hutchison-MRC Research Centre, University of Cambridge,
Cambridge, UK
Breast Cancer Res 2003, 5(Suppl 1):6 (DOI 10.1186/bcr665)
Mammary epithelium can be reconstituted in vivo by transplanting frag-
ments of mammary epithelium, or suspensions of mammary epithelial
cells, into the ‘cleared’ mammary fat pad of a syngeneic recipient
mouse. A ‘cleared’ mammary fat pad is one from which the natural
epithelium has been removed at 3 weeks of age. Genes can be intro-
duced into the epithelium before transplantation using retrovirus
vectors, or the epithelium can be taken from a knockout mouse [1]. The
applications of transplantation, and its advantages and disadvantages
compared with transgenesis will be surveyed, including the ability to
use hormone-insensitive promoters; to introduce genes into clones of
cells rather than whole tissues; the ease of studying early preneoplastic
change; and the use of transplantation with transgenic knockouts, to
rescue embryonic lethals and to distinguish systemic from local effects
[2].
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The Mutant Mouse Regional Resource Center
Program
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The Mutant Mouse Regional Resource Center (MMRRC) Program
serves as the National Institutes of Health (NIH) premier repository of
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spontaneous and induced mutant mouse lines. The MMRRC Program
was established in 1997 through a U01 funding mechanism from the
NIH National Center for Research Resources. The purpose of the
MMRRC Program is to ensure the continued availability of scientifically
valuable, genetically engineered mice and to distribute these mice to
qualified researchers studying human and animal biology and disease.
The MMRRC Program is made up of a national network of regional
breeding and distribution centers, in which UC Davis participates as
the West Coast regional Center. The facilities and personnel of the
MMRRC regional Centers cryopreserve and distribute mouse strains
with potential value in the research of human disease and biology.
These strains are then made available for distribution to qualified
researchers. Mice are supplied either from a production colony or from
a colony recovered from cryopreservation. MMRRC Centers also offer
cryopreserved material from some strains for resuscitation at the recipi-
ent scientist’s institution. The MMRRC at UC Davis is made up from
contributions of a number of UC Davis campus resources and units,
including the UC Davis Mouse Biology Program, the Center for Com-
parative Medicine, and the Center for Laboratory Animal Sciences. We
provide a host of services in support of the MMRRC Program, includ-
ing importation of mouse strains by rederivation, cryopreservation and
reanimation of frozen embryos and germplasm, assisted reproduction
techniques (in vitro fertilization, intracytoplasmic sperm injection, intra-
cytoplasmic nuclear injection), and comprehensive genotyping (includ-
ing speed congenics) and phenotyping (pathology, behavior, clinical
pathology, etc.) capabilities. As part of its participation in the MMRRC
Program, the MMRRC at UC Davis provides a comprehensive list of
services and procedures to insure safe and expedient importation,
maintenance, archiving, genotyping, phenotyping, and distribution of
mutant mouse lines. A number of these services and procedures are
provided at no charge to the Donating Investigator, while others are
offered for a fee to Requesting Investigators. In addition, using the
type 3 submission mechanism, a Donating Investigator can negotiate
with the MMRRC at UC Davis to perform selected services and proce-
dures on their mouse strain. For more information on the MMRRC
National Program, or to donate mice to, or request mice from, the
MMRRC please visit the website (www.mmrrc.org) or go to the
MMRRC at UC Davis website (http://mbp.compmed.ucdavis.edu/
modules.php?name=mmrrc).
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Genetically altered mice and cancer research:
effects of the other 99.999% of the genome and
other variables upon phenotype
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The modern laboratory mouse was derived from a diverse gene pool of
multiple species of the Mus musculus genospecies complex from
throughout Europe and Asia. The progenitors of laboratory mice were
thus hybrid species, but they subsequently underwent a genetic bottle-
neck at the beginning of the last century. Thus, the genomes of inbred
strains of mice, although homozygous, contain variable allelic contribu-
tions from this diverse origin, including endogenous retrovirus and
retrovirus-like elements. Domestication of the mouse through interna-
tional trading has also introduced over 60 infectious pathogens that
can cause overt disease, as well as more subtle effects upon research.
Burgeoning mouse populations and exchange among scientists have
led to the re-emergence of many of these agents. Genetic alteration of
the mouse often leads to atypical outcomes of these infections which
confound research. Diet, bedding, water, behavior, and other factors
also contribute to variable research results. Effective cancer research
should take advantage of the opportunity to utilize the mouse as a
genetically, microbially, and environmentally standardized animal model
system, but this requires global awareness of the biology of the labora-
tory mouse.
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Recent advances in multicolor flow cytometry have made possible the
simultaneous analysis of up to 12 distinct cell surface molecules. This
technical advance increases sensitivity and specificity for more accu-
rate diagnosis and classification of various malignancies. In turn, this
allows for a better assessment of disease prognosis and the establish-
ment of a treatment regimen. In addition, multicolor flow cytometry pro-
vides a sensitive technique for investigating the occurrence of minimal
residual disease. Studies of leukemias and lymphomas are particularly
suitable for investigation by flow cytometry. Studies on solid tumors
such as breast cancer, or on tumor infiltrating immune cells, are also
possible if appropriate processing techniques are used to generate
single-cell suspensions without altering cell surface receptor expres-
sion. In addition to analytical immunophenotyping, isolation of even very
small (malignant) cell populations by multicolor flow cytometry provides
a highly pure source for DNA and RNA analyses. Such combined
sorting and molecular approaches provide a comprehensive basis for
studying the molecular mechanisms underlying malignant transforma-
tion. Importantly, they also enable distinct diagnoses to be made when
cell surface marker immunophenotyping alone is inconclusive. To exem-
plify the importance of combining various immunophenotyping tools,
such as multicolor flow cytometry and gene expression analyses, with
the classical tools of histopathology and differential blood count, we
provide data on the analysis of a mouse model of human chronic B-cell
leukemia (B-CLL): the New Zealand Black mouse. We relied for this
study on gene expression databases generated by the National Cancer
Institute for various human B-cell malignancies. B-CLL is one of the
most common forms of leukemia in the Western world. No therapies
currently exist against this usually slow-progressing but always fatal
malignancy, making the development of a good animal model an impor-
tant task. The data show that although the New Zealand Black mouse
shows a spontaneous expansion of a CD5+ B-cell population (a hall-
mark of human B-CLL), it does not fit the classification of B-CLL by
either phenotypic or genetic analysis criteria. In conclusion, increasing
the number of simultaneous measurements for immunophenotyping
and cell sorting by flow cytometry and combining it with comprehensive
gene expression studies supports and expands the power of classical
analysis tools.
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Accurate diagnosis of lesions in genetically engineered mice requires a
level of experience and expertise that is not available in all institutions.
As a result, there is an unmet demand for the services of a limited
number of expert pathologists. In order to meet this demand, we have
developed several electronic, web-based educational and consulting
tools to expand the availability of expert pathologists.
Image Galleries The immediate need has been for publication quality
images that are connected to a robust database. This has been accom-
plished using a shareware program that is connected to our SQL
Mutant Mouse Pathology Archive database. This program develops
Image Galleries ‘on the fly’ that can display still images with demo-
graphic, genetic, and diagnostic information stored in the database.
The application includes a dialog box that permits the viewer and the
pathologist to exchange information and comments. However, the
images are limited to adynamic jpeg and tiff files that illustrate limited
fields selected by the photographer and do not display or annotate the
image in full context.
Available online http://breast-cancer-research.com/supplements/5/S1S4
Whole Slide Imaging To provide the digital view of the complete slide
in context, several new technologies have been merged to the Image
Archive using Whole Slide Imaging. Whole Slide images are digital
images of the entire block face or slide. These digitized images are
captured, compressed and viewed on any browser over the internet.
The digital image allows users to view entire microscopic images at any
magnification on their monitor. The images are captured with the
ScanScope (AperioTech Inc., Vista, CA, USA) in approximately
3–5 min at a resolution of 50,000 dpi, producing 8–20Gb of raw data.
To make the images accessible to the community, the images are
processed with the Zoomify compression algorithm which results in a
200–300Mb image that can be viewed with a standard web browser
using a Flash6 plug-in. The plug-in only downloads the pixels required
to render the view requested by the user (approximately 75kb/view).
The images can be annotated with layers that point to specific features
in the image allowing users to easily navigate to selected points of
interest within a slide while still being able to maneuver the entire slide.
Examples of these images can be viewed online (http://imagearchive.
compmed.ucdavis.edu).
Telepathology The full capabilities of the Zoomify system, have been
exploited by combining the Whole Slide Imaging with a Telepathology
Conferencing Tool that allows multiple simultaneous users to view the
same slide in session becoming a virtual multi-headed microscope. A
number of users can view, manipulate, and annotate a single image and
share their perspective utilizing the application’s voice conferencing
system (voice over). A preselected Moderator controls the conference
using a baton-passing utility that limits the number of users who can
manipulate the image at any given time. This system allows patholo-
gists to practice within a virtual world-wide group, gathering expert
opinions from widely dispersed locations. Every investigator will have
access to appropriate experts.
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Human breast cancer has been modeled in well over 100 types of
genetically engineered mice (GEM). Many of the mutated or over-
expressed genes found in human breast cancer also initiate mammary
cancer in GEM. The histopathology of GEM models of breast cancer
have proved to be unique. Most GEM tumors do not resemble the
spontaneous tumors induced by the mouse mammary tumor virus
(MMTV) or by carcinogenic agents. The pattern of some GEM tumors
closely resembles that seen in some human breast cancers. The most
provocative and most thoroughly studied GEM group belongs to the
ERBB2 (HER2) signal transduction pathway. GEM bearing ERBB2,
various forms of mutated ERBB2 and ERBB2-related genes produce
tumors via similar molecular mechanisms, and also have a remarkable
morphological resemblance to some forms of human breast cancer.
Tumors associated with tumor suppressor genes, such as Brca1 and
SV40 Tag (that suppresses expression of Rb and p53) tend to resem-
ble poorly differentiated tumors and, in some cases, medullary carci-
noma of the human breast. Many of the GEM develop mammary tumors
with characteristic or unique gene-specific ‘signature’ phenotypes that
readily can be identified microscopically. The principle that genotype
predicts phenotype can be applied to other GEM and extended to
include entire molecular pathways. Studies of tumor kinetics in bi-trans-
genic mice suggest that some combinations of genes are synergistic
while others are inhibitory. Although the majority of breast cancer
models have been induced using the MMTV-LTR as a promoter, C3(1),
WAP, and BLG promoters frequently have been used. Tumors retain
the phenotype characteristic of the oncogene, for the most part,
regardless of promoter. In some cases, inserting the transgene behind
the native promoter or ‘knocking-in’ an oncogenic variant at the normal
gene locus has also resulted in tumors characteristic of the oncogene.
GEM with inactivation of tumor suppressor genes generally die with
tumors other than mammary tumors. The mammary tumors that do
develop tend to be more poorly differentiated, aneuploid tumors with a
wider range of phenotypes. However, when crossed with GEM bearing
activated transgenes, the tumors are most likely to resemble the pheno-
type of the transgene. The tumors in bigenic mice do, however, have
more pleomorphic and aneuploid cells. The great majority of mouse
mammary tumors are hormone independent. This is in contrast to
human breast carcinomas, 50% of which express the receptors for
estrogen and progesterone, and are dependent (at least partially) on
these hormones for growth. The biology of metastasis is also quite dif-
ferent with mouse carcinomas displaying a hematogeneous spread
almost exclusively to the lung and with human carcinomas displaying
regional lymph node involvement with preferential systemic spread to
the bone, brain and liver.
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Positron emission tomography and X-ray
computed tomography: tools for mouse
phenotyping?
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Significant advances in imaging technology now permit non-invasive
imaging of mice with high spatial resolution and high sensitivity to bio-
chemical and molecular alterations. Two imaging technologies will be
discussed. X-ray computed tomography uses transmission of X-rays
through a mouse to create high-resolution anatomic images, which
can be useful for detecting phenotypic-related alterations in morphol-
ogy. Positron emission tomography utilizes trace amounts of radio-
pharmaceuticals to measure biologic function, for example glucose
metabolism, receptor binding and gene expression. Screening of
genetically engineered mice with positron emission tomography and a
radiopharmaceutical that correlates with glucose metabolism has
demonstrated sensitivity to phenotypic changes. Ultimately, the
merger of these two complementary imaging modalities, providing
spatially registered images of anatomy and function, may provide a
powerful tool for whole-body phenotypic analysis, although a number
of challenges must be addressed to realize a high-throughput imaging
tool for these applications.
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Genetically modified cancer models: the value of
luciferase-tagged tumors and in vivo luciferase-
based reporter assays in oncology drug discovery
W Yang, C Kowal, E Sorensen, P Lassota
Novartis Institutes for Biomedical Research, East Hanover, New
Jersey, USA
Breast Cancer Res 2003, 5(Suppl 1):13 (DOI 10.1186/bcr672)
Recent technological advances in visible light imaging allowed us to
use this technique to non-invasively detect and quantify tumor cells,
and to follow responses to drug candidates at molecular level in
mouse models of human cancers. Human prostate tumor cells tagged
with a firefly luciferase (PC-3M2AC6) were used in an orthotopic
model, and in a model of experimental bone metastasis in athymic
nude mice. Upon intravenous injection of D-luciferin these cells
emitted light, that could be non-invasively registered with a charged-
coupled device camera. Light emission was proportional to the tumor
burden. The assay had sufficient throughput to allow for screening of
advanced drug candidates for efficacy. Several compounds demon-
strated significant and reproducible activity against tumors growing in
prostates and in bones. These findings would not be possible without
the non-invasive method of quantitation of bone tumor burden. A
reporter gene, where luciferase is expressed from the p21waf-1 pro-
moter, was introduced into the H1299 human lung cancer cell line. So
constructed reporter cells were encapsulated in hollow fibers and the
fibers were implanted subcutaneously into athymic, nude mice. The
walls of hollow fibers are permeable to molecules up to 0.5MDa in
size, but not to cells. The animals were then treated intravenously with
various histone deacetylase inhibitors twice (24 and 32hours post
implantation); the fibers were retrieved from the animals 18hours after
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the last treatment, and were processes for light emission ex vivo.
Histone deacetylase inhibitors induced expression of luciferase and
thus light emission in the presence of D-luciferin. Results of this phar-
macodynamic 40hour assay were predictive of anti-tumor activity of
histone deacetylase inhibitors in mouse xenograft tumor models.
Therefore 5 week efficacy studies could be replaced with 2 day phar-
macodynamic assays. Preliminary results for the in vivo Caspase 3
induction assay will be presented.
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mammary tumors
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The long-term goal of our work is to better understand the mechanisms
of Herceptin action and resistance. Toward that end, we have pro-
duced transgenic mice that express HER2 under the control of the
mouse mammary tumor virus (MMTV) promoter. Transgenic mouse
models offer the advantage of having immune system components that
may be important in the action of antibodies but are lacking in immun-
odeficient hosts. ErbB2 transgenic mice have been produced by Muller
and colleagues using the rat homolog neu, which does not bind Her-
ceptin. Therefore, we made mice using the human version, HER2.
These mice express HER2 in the mammary gland at very high levels
and develop HER2-positive mammary tumors within 6–8 months.
Several tumors have been propagated as allografts in wild-type mice by
implanting a small piece of tumor into the mammary fat pad. Cohorts of
mice bearing the same tumor line were then treated with 4D5, the
murine version of Herceptin, or vehicle. Using this approach, we found
that several tumor lines are completely Herceptin resistant, others are
growth inhibited, and one regresses completely. As observed previ-
ously in tumors from neu transgenic mice, all of our HER2 tumors
contain small deletions in the juxtamembrane region of the HER2 tran-
script. Within a tumor line, each mutation is unique and remains stable
on continued passage. It is unclear, however, whether such mutations
are responsible for determining Herceptin sensitivity. Gene expression
profiling between the highly sensitive tumor line (F2-1282) and a
Herceptin-resistant line (Fo5) revealed a large number of differences
that could contribute to resistance. Gene expression profiling is also
being used to identify changes that take place in F2-1282, the
Herceptin-sensitive tumor, when it is exposed to Herceptin/4D5. In
summary, like individual breast cancer patients, tumors from MMTV-
HER2 mice display the entire spectrum of responsiveness to
Herceptin/4D5, from resistant to complete regression, and therefore
may help provide insights into cofactors that are important for
Herceptin activity.
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Tumor xenografts have been used for over three decades in oncology
drug development with little predictive value. A case has been made for
use of orthotopic xenograft models as well as transgenic tumor models
as a better reflection of tumor biology. However, their use in drug
development has been limited, thus far, due to technical challenges of
monitoring tumor growth. Recent advances in small animal imaging are
addressing some of those challenges; however, the predictive ability of
these models with regards to clinical response is still questionable.
This presentation will focus on the utility of animal models in oncology
drug development and a paradigm shift in their value as tools to evalu-
ate biological effects of new agents as well as understanding the phar-
macokinetic/pharmacodynamic relationship to aid in better clinical
development.
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beta as an important player in breast cancer
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Transforming growth factor betas (TGF-βs) play key roles in embryoge-
nesis, maintenance of adult homeostasis and response to injury. In
epithelial carcinogenesis the TGF-β play complex roles, functioning as
tumor suppressors early in the process, but as pro-oncogenic factors in
late-stage metastatic disease, when TGF-β ligands are frequently over-
expressed. To probe this complexity in vivo, and determine whether
TGF-β might be a viable therapeutic target, we developed a transgenic
mouse overexpressing a soluble TGF-β antagonist. This antagonist
(‘SR2F’) consisted of the extracellular domain of the type II TGF-β
receptor fused to the Fc domain of human IgG1. The SR2F was
secreted into the circulation and distributed to all organs except the
brain. To determine the effect of this TGF-β antagonist on breast car-
cinogenesis, the mouse mammary tumor virus (MMTV)-SR2F and wild-
type control mice were crossed with the MMTV-neu transgenic mouse
model of metastatic breast cancer. The neu/SR2F bigenic mice
showed a significant threefold decrease in the incidence of lung metas-
tases compared with mice expressing neu alone. A similar suppression
of metastasis was seen in using a tail vein injection model of metastatic
melanoma. Importantly, the SR2F did not accelerate primary tumorigen-
esis, despite the fact that TGF-β has been shown to function as a
tumor suppressor in the MMTV-neu model [1]. Furthermore, none of
the pathology that is usually associated with TGF-β loss, such as
autoimmune disease and increased spontaneous tumorigenesis, was
observed on prolonged exposure to SR2F. The mechanistic basis for
the unexpected selectivity of the SR2F in antagonizing the pro-metastatic
effects of TGF-β while sparing effects on tumor suppression and
normal homeostasis is currently not clear, but it does not seem to be a
dosage effect. Overall, our data suggest that high molecular weight
TGF-β antagonists might have promise in the clinic for prevention of
metastasis. This study demonstrates the utility of a transgenic
approach for testing expensive protein-based therapeutics in long-term
realistic models of cancer progression.
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Androgens control a broad range of physiological functions by binding
and modulating the activity of the androgen receptor (AR), a member of
the nuclear hormone receptor superfamily. The AR is a ligand-dependent
transcription factor that is widely distributed among reproductive and
non-reproductive tissues. It is predicted that, as in the case of the
estrogen receptor, different AR ligands will promote distinct pharmaco-
logical activities in different cell types depending on the specific trans-
criptional environment, that is the presence or the absence of specific
co-activators and co-repressors. In order to test this prediction in vivo,
we generated a transgenic mouse line (ARLUC) that expresses the
luciferase cDNA downstream of an androgen-responsive promoter
containing two copies of the 11-base pair DR-1 (5′-GAACG-
GAACA-3′) oriented as an overlapping direct repeat. This arrangement
demonstrated a strong preference for AR binding and transactivation
when compared with the glucocorticoid receptor [1]. Tissues with an
Available online http://breast-cancer-research.com/supplements/5/S1S6
active AR emit light when tested for luciferase activity that is detected
by the use of a cooled charged-coupled device camera or by direct
measurements of enzymatic activity in tissue extracts. Experiments
through biochemical analysis of tissue extracts showed expression of
luciferase in the testis, seminal vesicles, quadriceps, brain and bone
marrow. The luciferase expression was observed to be androgen-
dependent since it was dramatically diminished in castrated animals
and in animals treated with the anti-androgen bicalutamide compared
with intact animals. The use of such a model in the evaluation of AR
modulators will be discussed.
Reference
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Endocrine therapy, targeting estrogen production or the estrogen
receptor, is a crucial component in the treatment of breast cancer. This
has been recognized for over a century. Ovarian ablation is the oldest
form of endocrine therapy, first used in 1896. This presentation will
review: the history of endocrine therapy in the treatment of breast
cancer; endocrine strategies in premenopausal and postmenopausal
women; data on the use of endocrine therapy in early breast cancer;
new directions in the endocrine therapy of metastatic breast cancer;
and clinical implications of HER2-neu status and endocrine therapy.
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Pregnancy and lactation with breast feeding at an early age are the only
natural phenomena known to drastically reduce the risk for breast
cancer in women of all ethnicities worldwide. Parous rats and mice
(lacking mammary tumor virus) are also highly protected against chemi-
cally induced breast carcinogenesis. Our research goals during the
past 10 years have been to define the reason for the highly reduced
risk of the parous phenotype to breast cancers as well as to develop
safe, inexpensive, mechanism-based hormonal intervention procedures
mimicking the protective effects of pregnancy in rats. The first part of
our presentation will describe the development of two short-term treat-
ments, modified from Huggins and colleagues’ 1962 procedure, with
estradiol (E) and progesterone (P) in silastic capsules for 7–21 days.
We have acronymed these procedures as short-term E treatment
(STET) and short-term E+P treatment (STEPT). These treatments con-
taining late pregnancy levels of E, with or without P, for 7 days are suffi-
cient to reduce the breast carcinoma incidence by over 80% and
multiplicity by 90% in rats exposed to the potent carcinogen, N-methyl-
N-nitrosourea (MNU). Non-pregnancy or low early pregnancy levels of
E were ineffective in protecting rats against MNU-induced breast car-
cinogenesis. This has been the first demonstration suggesting that the
late pregnancy levels of estrogen may be the reason for the protective
effect of pregnancy in breast cancer risk reduction. The second part of
our presentation will focus on experiments characterizing the parous
phenotypes: Why are they protected against breast cancers? Our
results show that parous rats are not fully protected; they are suscepti-
ble to MNU-induced initiation and develop microscopic latent mammary
cancers. These rats are, however, protected from further promotion-
progression from developing into overt palpable cancers. Our results
also indicate that parous rats have persistently reduced mammogenic
hormones, growth hormone and prolactin as well as reduced levels of
the receptors for estrogen, progesterone and epidermal growth factor
in their mammary epithelial cells. The final section concludes by sug-
gesting that our treatment procedure for breast cancer prevention in
carcinogen-treated rats requires only 7 days of treatment (rat gestation
21 days) with no more than 1µg E/day and is as effective as full-term
pregnancy or ovariectomy or prolonged treatment with tamoxifen,
without any loss of ovarian function. Our results also suggest that
breast cancer protective effects of full-term pregnancy and short-term
treatments (STET/STEPT) are due to persistently decreased hormonal
environment for promotion-progression of the latent mammary cancers
to overt cancers.
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Estrogens are potent mitogens in a number of target tissues including
the mammary gland where they play a pivotal role in the development
and progression of mammary carcinoma. The demonstration that estrogen-
induced mitogenesis is associated with an increased rate of pro-
gression through the G1 phase of the cell cycle has focused attention
on the estrogen regulation of molecules in the cyclin/CDK/pRb
pathway that controls G1 to S phase progression. Steroid-responsive
breast cancer cells pretreated with a pure estrogen antagonist arrest in
quiescence (i.e. G0) and respond to estrogen treatment with synchro-
nous progression into the S phase. Entry into the S phase is preceded
by increased expression of c-myc and cyclin D1, activation of cyclin
D1–Cdk4 and cyclin E–Cdk2 complexes and phosphorylation of the
retinoblastoma gene product, pRb. Activation of cyclin D1–Cdk4 is due
predominantly to estrogen-induced transcriptional activation of cyclin
D1. In contrast, cyclin E–Cdk2 activation does not involve major
changes in cyclin E expression but rather redistribution of the p21 CDK
inhibitor away from cyclin E–Cdk2 complexes. This is mediated by two
distinct mechanisms: sequestration into newly formed cyclin
D1–Cdk4–p21 complexes and transcriptional inhibition of p21 gene
expression. In the same model progestins are growth inhibitory and
arrest cells in the G1 phase. Growth arrest is accompanied by
decreased expression of both cyclin D1 and cyclin E and induction of
the CDK inhibitor p18INK4C. These changes lead to reassortment of
cyclin–CDK–CDK inhibitor complexes and increasing availability of
p27 to form inhibitory cyclin E–Cdk2–p27 complexes. Thus, both
cyclin D1–Cdk4 and cyclin E–Cdk2 activities are inhibited, resulting in
decreased pRb phosphorylation and arrest in the G1 phase. These
data indicate that steroid hormones stimulate or inhibit cell cycle pro-
gression through effects on multiple targets in the pRb pathway. The
aberrant expression of several of these targets in breast cancer, i.e.
overexpression of c-myc, cyclin D1 and cyclin E and loss of expression
of p27, potentially contributes to the loss of steroid sensitivity and
endocrine resistance associated with the progression of breast cancer.
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The involvement of the ErbB receptor tyrosine kinases in human
cancer, as well as their essential role in various physiological events
during normal development, have motivated a high interest in this
receptor family. Approaches taken to block the activity of ErbB recep-
tors in cancer cells have not only proven that they drive in vitro tumor
cell proliferation, but have also become clinically relevant for targeting
tumors with deregulated ErbB signaling. The mechanisms and down-
stream effectors through which the ErbB receptors influence
processes linked to malignant development, including proliferation, cell
survival, angiogenesis, migration and invasion, are, however, only now
becoming apparent. We are very interested in how ErbB receptors, in
particular ErbB1 and ErbB2, contribute to processes linked to cancer
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progression. I will discuss the role of ErbB receptors in tumor cell pro-
liferation, migration, and induction of tumor vasculature.
22
Predicting breast cancer behavior by microarray
analysis
M van de Vijver
Department of Pathology, Netherlands Cancer Institute, Amsterdam,
The Netherlands
Breast Cancer Res 2003, 5(Suppl 1):22 (DOI 10.1186/bcr681)
In the treatment of breast cancer, patient-tailored therapy is becoming
increasingly important. Decisions on optimal treatment include the choice
between mastectomy and breast-conserving treatment; dose of radio-
therapy; and decisions on adjuvant chemotherapy and hormonal therapy.
Gene expression profiling by microarray analysis allows the study of the
level of expression of large numbers of mRNAs in a single experiment.
Gene expression analysis can be used to subclassify tumors on the basis
of hierarchical cluster analysis in specific subgroups; supervised cluster
analysis can be used to directly link gene expression profiles to clinical
characteristics, including prognosis and response to various forms of
treatment. We have used microarray analysis, first on a series of
117 breast carcinomas and more recently on a series of 295 breast car-
cinomas. We have defined a gene expression profile of 70 genes that is
predictive for a short interval to distant metastases.
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Genetically engineered mice have been used extensively to model
human breast cancer. Yet few have been developed and characterized
to model the progression from hyperplasia to cancer. We have devel-
oped a transplantable model for mammary hyperplasia that progresses
to invasive carcinoma, effectively mimicking human ductal carcinoma in
situ (DCIS). As such, this provides a unique model for chemopreven-
tion trials for high-risk premalignant breast lesions. These trans-
plantable lines, also known as mammary intraepihelial neoplasia
outgrowths (MIN-Os), were developed by our group and are derived
from the mammary hyperplasia of mouse mammary tumor virus-
polyomavirus middle T (mT) transgenic mice. The polyomavirus transgene
provides an attractive model for human mammary carcinoma, as it is
capable of transforming cells by triggering signal transduction path-
ways that have been implicated to be activated by erbB2, through inter-
actions between its mT gene product and key cellular signaling
proteins—such as c-Src, Shc, and phosphatidylinositol 3-kinase, which
have all been implicated as important in human breast cancer. These
transplanted lines are heterogeneous; however, within a line, through
multiple generations, the MIN-Os show consistent growth rate,
histopathology, and latency to tumor formation. The lines and the
tumors that arise from them maintain their defining characteristics in
‘tests by transplantation’. Histopathologically, the MIN-Os resemble
human DCIS, and the resulting mammary invasive carcinoma resem-
bles human invasive ductal carcinoma. With gene expression studies,
we have found dysregulated genes and pathways that have been
shown to be similarly altered in human DCIS, suggesting that our
model is related to DCIS not only at a histopathological level, but also
at a molecular level. These gene expression studies suggest the impor-
tance of stromal–epithelial interactions, the extracellular matrix
proteoglycan-mediated regulation of cell proliferation signaling, actin
cytoskeleton organization, and the insulin-like growth factors and their
effectors in the transition from hyperplasia to transformed invasive car-
cinoma. We have begun using this human DCIS model for developing
chemoprevention strategies for high-risk breast lesions. With in vitro
assays, we have ranked inhibitors for effectiveness and inclusion in in
vivo studies. We have demonstrated that inhibitors to phosphatidyli-
nositol 3-kinase and related downstream mediators are effective in
inhibiting growth. This mouse model provides an attractive platform that
is amenable to interventional studies and chemoprevention preclinical
trials, with easily measurable end-points for testing effectiveness of
agents while providing tissue for correlative molecular studies.
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Human tumors accumulate a remarkably diverse spectrum of recurrent
genomic abnormalities thought to reflect functional reprogramming of
the cancer cell phenotype. However, the causes and consequences of
many of these abnormalities are unknown. We describe here several
mouse-model-based approaches to functional interpretation of these
aberrations. Specifically, we demonstrate that integration of information
on recurrent aberrations in human breast tumors with information on
regions of susceptibility in mice and/or recurrent genomic abnormality
in breast tumors that arise in transgenic mice indicates regions of par-
ticular importance in human tumors. We also present evidence from
analyses of genomic abnormalities in tumors that arise in ‘RIP-Tag’
transgenic mice that both the genetic background and the temporal
dynamics of the initiating oncogenic event significantly affect the spec-
trum of abnormalities that arises during tumorigenesis.
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As part of a longstanding collaborative project within the Bay Area Breast
Cancer Translational Research Program (UCSF Breast SPORE), we have
continued to use nude mouse human breast cancer xenograft models to
test our hypothesis that more effective and less toxic delivery of potent
anticancer drugs can be achieved using immunoliposomes (ILs), consist-
ing of receptor-internalizing monoclonal antibody fragments covalently
linked to drug-encapsulated long-circulating liposomes (Ls). Our lead
agent, anti-HER2 immunoliposomes containing doxorubicin (anti-HER2
ILs-dox), now approaches clinical testing after preclinical evaluation and
optimization against multiple breast cancer xenograft models expressing
high (+3), moderate (+2), or low (+1) levels of the HER2/ErbB2 growth
factor receptor. The enhanced in vivo therapeutic index achieved by anti-
HER2 ILs-dox over immunoliposomes containing doxorubicin (+/– Her-
ceptin/trastuzumab) or free doxorubicin was found to be due to the
greater intracellular drug delivery achieved by receptor internalizing ILs. A
new bioassay measuring HER2 receptor internalization by ILs and per-
formed ex vivo on breast tumor cells or explants appears capable of identi-
fying a subset of HER2 overexpressing breast tumors that may not
respond to some HER2 receptor-targeted therapeutics. Other standard
breast cancer chemotherapeutics (e.g. vinorelbine, camptothecins) and
investigational agents (e.g. ellipticine, hydroxamic acid inhibitors of histone
deacetylase) have been similarly encapsulated and evaluated against
these tumor xenograft models, all showing enhanced therapeutic efficacy
by the targeted ILs>nontargeted Ls>free drug. Likewise, the modular
versatility of this drug delivery platform has been proven by linking drug-
encapsulated Ls with an epidermal growth factor receptor (EGFR)/HER1
targeting/internalizing antibody and demonstrating the significantly
improved efficacy and specificity of anti-EGFR ILs against EGFR overex-
pressing human breast cancer xenografts.
Available online http://breast-cancer-research.com/supplements/5/S1S8
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The overexpression and aberrant function of the epidermal growth
factor receptor (EGFR) (HER1, erbB1) and its ligands in several human
carcinomas have provided a rationale for targeting this signaling
network with novel treatment approaches. Based on the structure and
function of the EGFR, two anti-receptor strategies have been devel-
oped. The first strategy uses humanized monoclonal antibodies gener-
ated against the receptor’s ligand-binding, extracellular domain. These
antibodies block binding of receptor-activating ligands and, in some
cases, can induce receptor endocytosis and downregulation. The
second approach uses small molecules that compete with ATP for
binding to the receptor’s kinase pocket, thus blocking receptor activa-
tion and the transduction of post-receptor signals. In addition, these are
effective in blocking ligand-independent intracellular signals that later-
ally activate the receptor. Data will be presented in support of the
merits of using antibodies and small molecules in combination. The
transforming growth factor beta (TGF-β) signaling pathway is also
associated with metastatic tumor progression. Antibodies against
TGF-β ligands, small molecule inhibitors of the TGF-β type I receptor
(TβRI) serine/threonine kinase, and soluble TβRII:Fc fusion proteins are
anti-signaling approaches in development. Data suggest that both the
erbB and TGF-β signaling networks can synergistically contribute to
tumor progression. For example, signaling by the Ras/MAPK pathway,
downstream erbB receptors, has been reported to abrogate the anti-
proliferative effect of TGF-β in epithelial cells. Therefore, we have exam-
ined whether overexpression of HER2/neu (erbB2), a potent inducer of
Ras/MAPK signaling, modifies the inhibitory effect of TGF-β against
MCF-10A human breast epithelial cells. MCF-10A stably transfected
with a HER2 expression vector retained TGF-β receptors. Exogenous
TGF-β inhibited MCF-10A/HER2 cell proliferation and still induced
both Smad2 translocation to the nucleus and pCAGA-Lux reporter
activity. In wound closure and transwell assays, exogenous TGF-β
induced lamellopodia and actin stress fiber formation and motility of
MCF-10A/HER2 but not of control cells transfected with vector alone.
These effects were blocked by addition of the phosphatidylinositol
3-kinase inhibitor LY294002, the p38Mapk inhibitor SB202190, and
the MEK1/2 inhibitor U0126. The HER2 antibody Herceptin blocked
TGF-β-induced motility but not Smad-dependent reporter activity.
Infection with an adenovirus encoding a constitutively active TβRI
mutant (T204D) induced motility of MCF-10A/HER2 but not control
cells. In HER2-overexpressing cells, Rac1 and Pak1 were constitutively
associated with HER2. TGF-β enhanced this association as well as
MCF-10A/HER2 Rac1 activity as measured by Rac1 binding to a GST-
Pak binding domain fusion protein. Thus, overexpression of HER2
unmasks the ability of TGF-β to induce epithelial cell motility. This effect
is not limited to HER2 in that treatment of EGFR-amplified A431 squa-
mous cancer cells with TGF-β also induces motility which is blocked by
the EGFR tyrosine kinase inhibitor ZD1839. To follow these results, we
have generated mouse mammary tumor virus (MMTV)/
neu×MMTV/TGFβ1S223/225 bigenic mice. TGFβ1 delayed
mammary ductal extension in the bigenics compared with MMTV/neu
mice but mammary tumor latency was similar. Although the bigenic
tumors were smaller and less proliferative, they exhibited a higher histo-
logical grade and were more metastatic than MMTV/neu tumors.
Finally, TGF-β accelerated tumor cell intravasation in MMTV/
neu×MMTV/TGFβ1 bigenic mice compared with MMTV/neu mice.
These data suggest, first, cooperation between the erbB receptor and
TGF-β signaling in promoting the metastatic phenotype of human
breast cancer cells. Second, they imply that combined inhibition of mul-
tiple signaling networks in human cancer cells might be required in
order to meaningfully alter their natural progression.
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Animal models have been extensively used to test promising new agents
for the treatment and prevention of cancer. Many different animal
models are available for preclinical testing, and the choice of the spe-
cific model to use is often a critical step in successful drug develop-
ment. Many different mouse models of human breast cancer have been
developed that have been used to test promising anti-cancer drugs.
These include mouse models that spontaneously develop mammary
tumors, carcinogen-treated mouse models, xenograft models, trans-
genic mice and gene knockout mice that develop mammary tumors. The
particular strengths and weakness of these models for testing therapeu-
tic agents will be reviewed. The most widely used preclinical models for
testing agents for the treatment of cancer are xenograft models.
Xenograft studies using human cancer cell lines are easily conducted,
are relatively rapid and, importantly, are recognized by the Food and
Drug Administration as providing evidence of preclinical anti-tumor activ-
ity against human cancer. However, certain studies cannot be done
using xenografts of human cancer cell lines. These include testing of
immune-based therapies or testing of cancer preventive agents. For
such studies, other models are needed. Testing of novel vaccines
against cancer requires an immunocompetent host, and thus may
require vaccination against murine tumors or studies to be done in
‘humanized’ mice. Studies of cancer preventive agents requires
xenografts of human normal breast tissue or carcinoma-in-situ lesions,
or alternatively mouse or rat models that develop tumors, either sponta-
neously or after carcinogen treatment. One of the most commonly used
models for testing chemopreventive agents has been the carcinogen-
treated rat model. This model has been successfully used to demon-
strate the chemopreventive activity of many agents, including selective
estrogen receptor modulators (SERMs) such as tamoxifen, raloxifene,
and idoxifene, and retinoid compounds, and is particularly useful for
testing agents for the prevention or treatment of estrogen receptor-
positive mammary cancer. More recently, transgenic mouse models
have been used to study the activity of chemopreventive agents, particu-
larly for the prevention of estrogen receptor-negative breast cancer. We
have used two such transgenic mice (C3(1)-SV40 T antigen, and
mouse mammary tumor virus [MMTV]-erbB2 mice) to investigate the
preventive activity of receptor-selective retinoid compounds. Both of
these transgenic mouse lines develop premalignant lesions that then
evolve into invasive mammary tumors that eventually metastasize. We
have found that 9-cis-retinoic acid, which binds both retinoic acid receptors
and retinoid X receptors (RXRs), and the RXR-selective retinoid,
LGD1069 (bexarotene, Targretin), suppresses the development of non-
invasive and invasive mammary tumors in both C3(1) SV40 T antigen
mice and MMTV-erbB2 mice. These retinoids interfere with tumorigene-
sis by suppressing proliferation of normal and premalignant mammary
epithelial cells, ultimately suppressing the development of invasive
cancer. Based on these results in these mouse models, we initiated a
human clinical trial using retinoids for the prevention of human breast
cancer, which is now ongoing. These results demonstrate the utility of
genetically engineered mouse models for the testing of molecularly tar-
geted agents for the prevention of breast cancer.
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Intact cyclin D1 functions are essential for transformation by erbB2. We
have used transgenic models, tissue culture experiments and human
tumor samples to particularly address the role of cyclin D1–cyclin
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dependent kinase interactions in transformation by erbB2. The p16
tumor suppressor specifically blocks cyclin dependent kinase 4 (Cdk4)
activity and blocked tumorigenesis by erbB2, demonstrating that
deregulation of the cyclin dependent kinase partner of cyclin D1 is an
essential target of erbB2. We then investigated the uses of a candidate
drug that inhibits Cdk4 in erbB2-mediated tumorigenesis. Individual
drugs active against ErbB2 and cyclin D1 (Herceptin and flavopiridol)
were synergistically cytotoxic against ErbB2-positive breast cancer.
The addition of flavopiridol to Herceptin synergistically lowered erbB2
levels in these cells. Our data suggest the potential use of combina-
tions of cyclin dependent kinase inhibitors and Herceptin in breast
cancer and form the basis for an ongoing trial of this drug combination.
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The rat is an important murine model for biomedical research. It is a key
model for many diseases including cardiovascular diseases, diabetes,
neurological diseases, and certain cancers such as breast cancer.
Through much work the rat genomic toolbox is almost full and includes
dense genetic maps, an approximately sevenfold genomic sequence
and transgenic technologies. A key missing tool was the ability to
produce knockout rats. This was in part due to the fact that despite
over a decade of work embryonic stem cells could not be made to go
germline. In order to approach this problem we developed a unique
technology that combined the use of germline mutagenesis with a
yeast truncation gap repair assay to select gene-specific knockout rats.
We first developed the protocols to efficiently mutagenize the rat
genome with ethyl nitroso urea. In order to establish knockout rats for
specifically chosen genes, we bred ethyl nitroso urea mutagenized
males with untreated females to produce F1 pups. These pre-weanling
pups were screened for functional mutations (e.g. nonsense mutations,
out of frame-shifts mutations, etc.). This was accomplished using a
highly efficient and economical yeast gap-repair truncation assay. For
this assay either genomic DNA or cDNA is produced from tail clips of
rat pups. This DNA is then used as a PCR template to amplify the tar-
geted gene sequence. This unpurified PCR product together with our
reporter vector is cotransformed into yeast that does not express
ADE2. The yeast through homologous recombination clones the PCR
product into the non-integrated ADE2 reporter plasmid. In scoring the
yeast plates, a negative plate has mostly white large colonies and a
plate positive for a knockout allele has one-half red colonies (rat) and
one-half white colonies. We have used this technology to knockout two
breast cancer suppressor genes, Brca1 and Brca2. The technology
described can be applied to most rapidly breeding species ranging
from zebra fish to mice.
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This presentation will discuss the strengths and weaknesses of cur-
rently available mouse models for mammary cancer. The major underly-
ing premise is that we cannot understand, investigate, and hopefully
cure breast cancer without animal models and that for a variety of bio-
logical, scientific, economic, and ethical reasons rodents represent the
best available model systems for mammary cancer. This being said,
how accurately do rodent models reflect the human condition and what
are the characteristics of an ideal model system? Do they reflect the
molecular complexity and stochastic nature of human breast cancer
and do they represent an appropriate format for testing of newly devel-
oped agents that specifically interact with designated molecular
targets? In addition, a case will be made for understanding the natural
history of mammary cancer following treatment and that too often the
development of a tumor is seen as an endpoint and not as a beginning.
Finally, it is clear that we have a very poor understanding of precursor
lesions in rodents and it will be critical to understand how these relate
to fully developed malignant tumors before the full potential of these
models can be realized.
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Ductal carcinoma is the malignant disease most frequently diagnosed
in American women. This cancer type originates in Stem Cells 1,
epithelial cells that are the main components of the undifferentiated
mammary gland. The susceptibility of Stem Cells 1 to become trans-
formed has been attributed to their high rate of cell proliferation, their
ability to bind and activate the carcinogen and their low DNA repara-
tive activity. Epidemiological evidence indicates that a woman’s life-
time risk for developing breast cancer is decreased by a full-term
pregnancy at a young age. The protection conferred by pregnancy is
the result of the differentiation of the organ. The reproduction of the
hormonal milieu of an early full-term pregnancy by administration of
human chorionic gonadotropin (hCG) to virgin rats induces lobular
development, completing the cycle of differentiation of the breast that
converts the highly susceptible Stem Cell 1 into a resistant Stem
Cell 2 through a process of induction of a specific genomic signature
in the mammary epithelium. Both pregnancy and hCG exert a protec-
tive effect on the mammary gland by reducing the incidence of 7,12-
dimethyl-benz(a)anthracene (DMBA)-induced carcinomas. Although
differentiation significantly reduces cell proliferation in the mammary
epithelium, the differentiated Stem Cell 2 remains capable of
responding with proliferation to given stimuli, such as a new preg-
nancy; it is also capable of metabolizing the carcinogen and of repair-
ing DNA damage more efficiently than the Stem Cell 1. The basic
biological concept is that the conversion of the susceptible Stem
Cell 1 to a refractory Stem Cell 2 after pregnancy or hCG treatment
of virgin rats results from the differentiation of the mammary gland, a
phenomenon manifested at morphological, cell kinetic and functional
levels. Morphological changes consist of a progressive branching of
the mammary parenchyma and lobule formation, which in turn result
in a reduction in cell growth fraction and lengthening of the cell cycle.
The functional changes comprise increased synthesis of inhibin,
β-casein and other milk-related bioactive peptides. In addition, preg-
nancy or hCG also increases the expression of programmed cell
death genes, including TRPM2, ICE, p53, c-myc, and bcl-XS, induc-
ing as well apoptosis, and downregulation of cyclins. Programmed
cell death genes were activated through a p53-dependent process,
modulated by c-myc, and with partial dependence on the bcl-2
family-related genes. Data generated using the cDNA microarray
techniques have allowed us to demonstrated that while lobular devel-
opment regressed after the cessation of pregnancy or hormone
administration, programmed cell death genes remained activated,
and new sets of genes reached a peak of maximal expression while
others became downregulated, creating a genomic signature that is
specific for both pregnancy and hCG treatment, but significantly dif-
ferent from those induced by the ovarian steroid hormones estrogen
and progesterone. These mechanisms play a role in the protection
exerted by hCG from chemically induced carcinogenesis, and might
be even involved in the life-time reduction in breast cancer risk
induced in women by full-term and multiple pregnancies. In addition,
hCG inhibits the progression of DMBA-induced mammary tumors on
the early phases of tumor progression (i.e. intraductal proliferation, in
situ carcinomas and invasive carcinomas). These observations led us
to infer that hCG, like pregnancy, induces early genomic changes
that lead the mammary gland to full differentiation, and that these
changes result in a permanently imprinted genomic signature that
regulates the long-lasting refractoriness of the mammary gland to car-
cinogenesis. The permanence of these changes makes them ideal
Available online http://breast-cancer-research.com/supplements/5/S1S10
surrogate markers of hCG effect in the evaluation of this hormone as
a breast cancer preventive agent.
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Estrogens are inextricably linked to the etiology of breast cancer. We
have demonstrated that the ACI rat strain exhibits a unique propensity
to develop mammary cancer when treated continuously with 17β-estra-
diol (E2). Treatment of ovary intact ACI rats with E2 results in virtually a
100% incidence of mammary carcinoma with a median latency of
approximately 140 days. These mammary cancers are dependent upon
exogenous E2 and exhibit genomic instability, a hallmark of breast
cancers in humans. In contrast, the Copenhagen (COP) and Brown
Norway (BN) rat strains are resistant to E2-induced mammary carcino-
genesis. Susceptibility to E2-induced mammary cancer behaves as an
incompletely dominant or dominant trait in crosses between the ACI
strain and the COP or BN strains. Genetic linkage analyses of several
hundred phenotypically defined F2 progeny from reciprocal crosses
between the ACI and COP or BN strains revealed a total of seven
genetic determinants of susceptibility to E2-induced mammary cancer
on chromosomes 2, 3, 4, 5, 6, 7 and 18. The chromosome 5 locus,
designated Emca1, determines susceptibility to E2-induced mammary
cancer in reciprocal crosses between the highly susceptible ACI strain
and the resistant COP or BN strains. Potential candidate genes resid-
ing within the Emca1 locus include Cdkn2a, Cdkn2b and Cdkn2c.
Studies on Cdkn2a indicate that expression of the p16Ink4a protein
product of the Cdkn2a locus is downregulated at an early stage of
E2-induced mammary carcinogenesis in the ACI rat. We are currently
evaluating these genes further to determine whether and how they con-
tribute to mammary cancer etiology in this model.
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The pluripotent cytokine transforming growth factor β 1 (TGF-β) can
inhibit epithelial proliferation, induce apoptosis and modulate stromal
composition. Our studies indicate that epithelial TGF-β production and
activity are differentially regulated by estrogen and progesterone during
normal mammary gland development and that, in turn, TGF-β regulates
epithelial apoptosis and proliferation in a hormone-dependent manner.
Our observation that TGF-β activity co-localizes in estrogen receptor-
positive cells and that TGF-β depletion increases their frequency and
proliferation supports the conclusion that it is a functional determinant
of cell fate decisions in response to hormones. Although TGF-β is char-
acterized as a classic tumor suppressor, it can also promote cancer
progression. We have shown that the TGF-β signal pathway is rapidly
activated as a consequence of ionizing radiation exposure, which is a
known breast carcinogen; its role in DNA damage response is not
known. We found that mice heterozygous for deletion of the TgfB1 gene
fail to undergo cell apoptosis and cell cycle delay in response to DNA
damage. Furthermore, TgfB1+/– mammary epithelial cells fail to appropri-
ately activate p53, indicating that the TGF-β ligand is essential for induc-
tion of rapid molecular responses to DNA damage that determine cell
fate decisions. Thus, TGF-β action during DNA damage response sup-
ports its role as a tumor suppressor. Its loss during carcinogenesis
would contribute to genomic instability and promote tumor progression,
and in particular may be relevant to the genesis of estrogen receptor-
positive tumors.
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Mammary morphogenesis is the result of the complex interplay of pro-
lactin (PRL), estrogen (E), progesterone (P) and growth factors. The
spatio-temporal patterns of hormone and growth factor action on the
epithelial and stromal compartments during development and differenti-
ation of the mammary gland give vital clues to cell fate. Concurrent with
the morphological changes in the gland during puberty, progesterone
receptors (PR) localize at early branch points. During peripubertal mor-
phogenesis PR distribution shifts from a homogeneous to a heteroge-
neous pattern The Hox-related, homeobox containing gene, Msx2, is
highly expressed during branching morphogenesis where our studies
in vivo and in vitro show that its expression is regulated by P in the
presence of E. The overexpression of Msx-2 in stable transfectants of
the ‘normal’ mouse mammary epithelial cell line, NmuMg, results in a
highly branched phenotype compared with control cells transfected
with the empty vector (EV) when grown in collagen gels. The NmuMg-
Msx2 cells constitutively overexpress cyclin D1 and form multiple large
colonies when grown in soft agar. When the NmuMg-Msx2 were
implanted into nude mice either subcutaneously or in the mammary fat
pad, rapidly growing tumors arise within 8 weeks in 97% of the mice
compared with small, slow-growing tumors in 42% of animals given the
NmuMg-EV cells. PRL, in concert with P, acts during ductal branching
and alveologenesis within the mammary gland. As the animal matures,
the distribution of the PRL receptor in the epithelium, like that of the
PR, progresses from a homogeneous to a heterogeneous pattern, sup-
porting our hypothesis that these hormones synergize to stimulate
epithelial and stromal proliferation.
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LEF1, a member of the LEF1/TCF transcription factors, is a component
of the canonical Wnt-signalling pathway. The Lef1 knockout mouse
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(Grosschedl) lacks hair, vibrissae, teeth, and mammary glands—all
derivatives of the ectoderm. Experimental analysis of the role of LEF1 in
tooth development has revealed an entirely non-cell-autonomous func-
tion—rather surprising for a component of a signal reception pathway. In
fact, Lef1-deficient tooth development can be fully rescued by recombi-
nant fibroblast growth factors, indicating that the sole function of LEF1
in this organ is to link Wnt- and fibroblast growth factor-signalling activ-
ities. Apparently, LEF1 is a crucial transcription factor regulating epithe-
lial–mesenchymal interaction. Basically, a similar role of LEF1 was
found in vibrissa (whisker) development but its function in mammary
gland development remains enigmatic. Mammary buds do form in
E11/12 mutant embryos, persisting (with variable penetrance) for
2–3 days, but no glands ever grow out. Although mutant mammary
glands occasionally do develop in culture, no defined factors were
found to be capable of rescuing mammary development. Our prelimi-
nary results indicate an additional function of LEF1 in mammary devel-
opment, possibly in establishing mammary versus epidermal cell fate.
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Breast cancers are heterogeneous and consist of several pathologic
subtypes with different histological appearances of the malignant cells,
different clinical presentations and outcomes, and the patients show a
diverse range of responses to a given treatment. Furthermore, breast
tumor tissue also shows heterogeneity with respect to its microenviron-
ment including specifically the types and numbers of infiltrating lympho-
cytes, adipocytes, stromal and endothelial cells. The cellular
composition of tumors is a central determinant of both the biological
and clinical features of an individual’s disease. We have performed
expression studies of more than 300 breast carcinomas of different
stages and histological subtypes, using high-density cDNA microar-
rays, aiming at novel tumor classification that can predict survival and
treatment response. The expression patterns observed provided a
remarkably distinctive molecular portrait of each tumor. The tumors
could be classified into five novel subtypes (two luminal epithelial
derived estrogen receptor-positive tumor subtypes, a basal epithelial-
like, an ERBB2-positive group, and a normal breast-like group). Survival
analyses showed significantly different outcome for patients belonging
to the various subtypes, including a poor prognosis for the basal-like
and a significant difference in outcome for the two luminal/estrogen
receptor-positive subtypes. Differences in TP53 mutation frequency
between the subtypes indicated an important role for this gene in
determining the gene expression pattern in the various tumors. The fre-
quency of the different genotypes of the codon 72 polymorphism of the
TP53 genes was significantly different in the five subgroups identified
by expression analysis, indicating that the TP53 genotypes also have
an impact on the expression profile. Unequal distribution of the different
genotypes of the CYP19 gene between the different subgroups was
also observed. Cluster analyses of two published, independent data
sets representing different patient cohorts from different laboratories,
uncovered some of the same breast cancer subtypes. In the one data
set that included information on time to development of distant metas-
tasis, subtypes were associated with significant differences in this clini-
cal feature. By including a group of tumors from BRCA1 carriers in the
analysis we found that this genotype predisposes to the basal tumor
subtype. Our results strongly support the idea that many of these
breast tumor subtypes represent biologically distinct disease entities,
and that both the patient’s genotype and the tumor genotype have a
strong influence on the expression pattern developed in a given tumor.
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Germline alterations in the BRCA1, BRCA2 and CHK2 genes were
analysed in a series of breast cancer cases from the Icelandic popula-
tion of 285,000 and risk was estimated. By screening 1172 cancer
patients for the detected T59K sequence variant in the CHK2 gene, it
was detected in a total of four breast cancer patients, two colon cancer
patients, one stomach cancer patient and one ovary cancer patient, but
not in 452 healthy individuals. The results suggest a tumor suppressor
function for CHK2 in a small proportion of breast tumors and that the
T59K CHK2 sequence variant is a low-penetrance allele with respect
to tumor growth. A rare mutation was detected in the BRCA1 gene and
a frequent mutation in the BRCA2 gene. The BRCA2 999del5 is clas-
sified as a founder mutation and the Icelandic population-based analy-
sis gives an excellent opportunity to define the risk of this sequence
variant for breast cancer and other cancer types. The BRCA2 999del5
mutation is present in 7% of unrelated breast cancer patients in
Iceland, the prevalence increases with lower age of diagnosis and the
estimated breast cancer risk in mutation carriers at the age of 70 years
is 40%. A detailed analysis was done on the somatic events in tumors
of 46 BRCA2 999del5 carriers with respect to genomic instability and
gene alteration. Chromosome alterations were elevated and of specific
architecture compared with sporadic cases, in line with the DNA/chro-
mosome repair function of Brca2. An alternative mechanism of TP53
involvement seems to be specific to the pathogenesis of BRCA2
999del5 tumors. Furthermore, alterations at the FHIT gene located at
the FRA3B locus with subsequent reduced expression seem to be of
specific relevance in the BRCA2 tumors.
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Comparative genomic approaches have been used extensively to iden-
tify DNA sequences involved in the regulation of conserved human
genes. These approaches are indeed powerful, permitting the ~5% of
the genome that is comprised of critical functional elements to be dis-
tilled from the background of non-conserved DNA. Using genome
alignment tools, promoters, enhancers and other types of regulatory
sequences can be identified, providing ready access to DNA sequence
elements that are difficult to identify by other means. Comparative
genomic alignments can also reveal the presence of novel genes.
However, while most studies focus on sequences that are similar
between the human and the mouse, the differences between the two
genomes are also revealing, exposing different mechanisms of gene
regulation and function and even gene-content differences in humans
and rodents. Both the similarities and differences in genomic structure
are critical to the interpretation of rodent models for human disease.
We are using comparative genomic approaches to define genes and
regulatory elements associated with imprinting and developmental dis-
orders in the mouse model system. I will discuss new data arising from
the analysis of mouse mutant models expressing developmental disor-
ders and susceptibility to cancer. In each case, comparative genomics
approaches have been critical to identification of genes and regulatory
elements that are central to development of disease-related symptoms
in the animals. Differences in gene regulation and structure revealed by
these studies will also aid in exptraloting results from these mouse
models to similar diseases in human patients.
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Imaging the mouse has become a valuable adjunct to genomic and
cancer research. Although tomographic techniques such as high-
resolution positron emission tomography (microPET) and computed
tomography (microCT) are extremely useful, there is also a need for the
rapid assessment of mouse anatomy and function at very low radiation
doses, with low cost and high throughput. A system was designed
using a stimulable phosphor BaFBr imaging plate (commonly called
computed radiography [CR]) as the detector. A planar emission image
(I-125) is acquired onto one side of the 18cm×24cm CR detector.
Subsequent to the emission image acquisition, precise translation of
the mouse platform over the CR plate allows the acquisition of an X-ray
radiographic image onto the other side of the same CR plate. The
image is then read out in a CR reader, which produces a 1770×2370
pixel digital image with 0.100mm pixel pitch. The I-125 and X-ray
images are extracted from the larger image, and are mechanically regis-
tered, allowing the functional I-125 emission data to be overlaid onto
the anatomical X-ray image. Because the CR imaging plates and other
required hardware are relatively inexpensive, it is possible that up to
20 mice could be imaged simultaneously using 20 imaging plates,
limited only by how many mice can be safely anesthetized and moni-
tored by the technician(s). Once the mice are safely back in their
cages, the CR plates can then be read out and the images processed.
The overall design of the dual imaging system will be discussed, and
the results of a prototype system currently in our laboratory will be
presented. Monte Carlo techniques were used to assess the X-ray-
associated radiation dose levels with the hybrid imaging system, and
the findings suggest that the radiation levels due to the X-ray
procedure are far lower than for microCT. We conclude that for appro-
priate research applications such as monitoring tumor growth over
time, or monitoring tumor regression due to therapy, the hybrid imaging
system may provide useful tumor kinetic information with high spatial
and temporal resolution, and using low radiation dose levels.
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Positron emission tomography (PET) is a nuclear imaging method that
produces quantitative three-dimensional images of the distribution of
positron-labeled radiotracers in vivo. Recent dramatic improvements in
spatial resolution, and the development of dedicated small-animal PET
scanners, now enable PET imaging studies to be carried out in mice.
This allows the initiation, development and progression of cancer to be
monitored longitudinally within individual animals. We will show exam-
ples of how PET is being used to track tumor development, and to
detect early tumor response to chemotherapy. We will also show that
potential therapeutics can be directly radiolabeled and how their
biodistribution and concentration at the target site can be measured by
PET imaging. The advantages and disadvantages of PET imaging com-
pared with other imaging modalities will be discussed.
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Tumor growth, local invasion, and metastatic dissemination are depen-
dent on the formation of new microvessels. Angiogenesis is therefore a
crucial event in tumor progression. In recent years anti-angiogenic
agents have been developed as a novel approach to cancer treatment.
Successful intervention with tumor angiogenesis can induce tumor vas-
culature regression, leading to a complete cessation of tumor growth.
Clinically, however, anti-angiogenesis inhibitors have been used with
marginal success. For the development of novel effective anti-angiogenic
therapies it is of crucial interest, therefore, to be able to screen
new treatments for both the effects on the tumor vasculature as well as
the tumor burden itself. We have engineered the murine breast cancer
cell line 4T1 to stably express the luciferase gene of the North Ameri-
can firefly. This allowed us to visualize tumor burden by in vivo biolumi-
nescence imaging. The 4T1 mouse mammary carcinoma is derived
from Balb/c mice and very closely models advanced stage (stage IV)
human breast cancer in immunogenicity, metastatic properties and
growth characteristics. Additionally, we have developed the
adapter/docking tag system based on interactions between an
18–127 amino acid fragment of human RNase I and a 1–15 amino acid
fragment of RNase I fused to a targeting protein. To visualize angiogen-
esis we applied to the docking system labeling vascular endothelial
growth factor with 99mTc in 4T1 breast cancer tumor-bearing mice. In
preliminary studies we were able to detect neovascularization in mouse
breast cancer tumor nodules as small as 2–3mm in diameter. We
found that the 99mTc-labeled vascular endothelial growth factor com-
plexes selectively and specifically bound to tumor neovasculature. We
expect that 99mTc-Adapter, a broadly applicable and general humanized
radionuclide imaging ‘payload’ module, can be readily employed for a
non-destructive labeling of many targeting proteins armed with the
docking tag. Availability of multiple imaging proteins might have
tremendous implications for the development and evaluation of novel
anti-cancer and, specifically, anti-angiogenic therapies.
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Our goal is to evaluate the use of ultrasound to detect small regions of
increased vascular density and altered blood flow and to quantify small
changes in these parameters due to effects of new anti-angiogenic
drugs. Regions containing intravascular contrast agents are identified
using a new ultrasound strategy that combines subharmonic and phase
inversion imaging. The contrast agent is repeatedly destroyed in order
to estimate the time required for local replenishment. Parameters are
estimated based on this strategy and include measures of the spatial
extent of flow, the spatial integral of flow, and the time required for 80%
replenishment. In a study of 25 tumors, we first demonstrate that
regions of viable tumor as small as 1mm, as verified by histology, can
be detected and show similar morphology to images acquired with
computed tomography (CT). The spatial mapping of vessels with ultra-
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sound is superior to contrast enhanced computed tomography due to
the intravascular distribution of ultrasound contrast agents. Estimation
of the time to 80% replenishment was conducted on kidney and tumor
data and is a robust parameter not altered by attenuation. Mean times
to 80% replenishment of 1–5s were estimated for the kidney cortex
and mean times of 6–14s were observed for viable tumor tissue. This
broad range of replenishment times is indicative of abnormal tumor vas-
cular density and tortuosity. Changes in flow parameters with anti-
angiogenic therapy are significant beginning at 48 hours post-treatment.
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I will describe some of the activities taking place in our National
Science Foundation-sponsored Center for Biophotonics Science and
Technology. The mission of this center is the application of photonics
to the grand challenges of biosciences and medicine. Some examples
of these challenges include imaging of single biomolecules within living
cells and development of non-invasive diagnostic and therapeutic
medical devices. Our Center currently sponsors 20 different research
projects that involve interdisciplinary researchers from 10 different col-
laborating institutions. These institutions are UC Berkeley, UC San
Francisco, Stanford University, Mills College, Lawrence Livermore
National Laboratory, UT San Antonio, Hampton University, Alabama
A&M University, Fisk University as well as UC Davis. Projects focus on
developing new technologies for imaging from the whole organism to
the single molecule levels. These technologies include biolumines-
cence, non-linear optical, X-ray laser and free-electron laser
microscopy. We are also developing optical sensors that can be used
for monitoring the biochemistry of living cells as well as detecting dis-
eases at the level of single molecule sensitivity. Of particular emphasis
is our work on portable monitors for infectious biologic agents. We like-
wise are developing new medical device technologies based on photo-
activated materials, laser fluorescence as well as scattering and
absorption spectroscopy. I will also discuss our industry partnership
programs as well as opportunities for new collaborations and partnering.
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Premalignancy in mouse models has been studied for the past
50 years. These present as epithelial hyperplasia; several types of
which occur in the mouse mammary gland depending on the initiating
stimulus. Alveolar hyperplasias are frequently observed in models
where mouse mammary tumor virus, hormones or chemical carcino-
gens are the initiating agents. Ductal hyperplasias are frequently
observed in genetically engineered models where specific oncogenes
have been deregulated. The premalignant nature of these lesions can
be verified by transplantation into the mammary fat pads of either syn-
geneic or immunocompromised mice. The alveolar hyperplasias gener-
ate tumors that are frequently estrogen-receptor negative and diploid,
although metastatic to lung. Estrogen receptor expression is downreg-
ulated early in premalignant progression, often when the hyperplastic
lesion is first identified. The ductal hyperplasias progress through
ductal carcinoma in situ and generate tumors that are frequently estrogen-
receptor negative but the tumors are aneuploid. In recent years,
premalignancy in genetically engineered mice has been extensively
characterized at the biological level in p53 null mammary epithelium
and in polyoma MT mammary gland, and to a lesser extent in the
SV40LT antigen mammary gland. The molecular alterations in these
lesions are beginning to be analyzed by array methodologies. These
models provide the opportunity to identify early events causal in prema-
lignant progression as well as to test the efficacy of agents that prevent
progression.
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Mouse models of human mammary intraepithelial neoplasia have been
described in a number of contexts. In general, descriptions of early
stages of progression in genetically engineered mice that go on to
develop invasive and even metastatic carcinomas are compared with
human ductal carcinoma in situ (DCIS). In some instances, lesions with
phenotypic similarity to human DCIS are compared, even without evi-
dence of progression. The terminology for these processes in the
mouse mammary gland requires precise definition. Otherwise, it is
impossible to compare the variety of available models for study utility.
Experimentally driven operational definitions are optimal. We have
studied a series of transplantable mammary intraepithelial neoplasia
outgrowths (MINOs) derived from the transgenic mouse mammary
tumor virus promoter-driven polyoma virus middle T oncogene FVB
mice. We have characterized their behavior experimentally and morpho-
logically. Experimentally, these MINOs meet the most stringent criteria
to be considered premalignant. They are capable of orthotopic growth
in the gland cleared mammary fat pad, are without being capable of
ectopic (subcutaneous) growth, and have a consistent transformation
to the fully malignant behavior (capable of ectopic growth)—defined
therefore as invasive carcinoma. Morphologically, there is a high
degree of heterogeneity both within and between individual MINO
lines. Nevertheless, all consistently transform to behaviorally and mor-
phologically similar carcinomas. MINOs therefore compare closely with
human DCIS. Human DCIS is similarly defined by its universal potential
(if incompletely treated) to progress to invasive carcinoma, despite het-
erogeneity within a given breast or between individual patients. We
extend the comparison using immunophenotypic analysis, and gene
expression analysis. Overall, our goal is to better model human DCIS, in
a reproducible and robust mouse model system suitable for interven-
tional studies. By creating a serially transplantable series of MINOs we
have removed much of the variability which would otherwise confound
such study. Derivation of MINOs from a variety of genetically engi-
neered mice backgrounds may provide additional critical reagents for
the preclinical study of DCIS.
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With increasing sensitivity of methods of detection, microscopic lesions
are being identified which produce a diagnostic dilemma for the pathol-
ogist. This is because their natural history is largely unknown. Some
postmortem studies would suggest that what a pathologist would call a
potential precursor lesion for invasive breast cancer may be present with
an incidence as high as 40% in some age groups. Although we are now
beginning to understand the spectrum of protein, RNA expression, gene
mutations and epigenetic changes in breast cancer, this is a long way
from being able to predict from a single lesion what its potential is to
invade or metastasise. It is, however, reassuring that the recent
advances in stem cell biology in the breast may assist in the identifica-
tion of the potential target cells for carcinogenesis. These studies have
relied on the use of classical markers for fully differentiated luminal and
myoepithelial/basal cells. The current vogue to classify tumours on the
basis of microarray data as ‘basal-like’ or lumenal may be leading us into
Available online http://breast-cancer-research.com/supplements/5/S1S14
assumptions about histogenesis that are not proven. Whether these
studies will assist in identifing preneoplasia will be discussed in relation
to our current knowledge on the evidence for myoepithelial and lumenal
cell differentiation in human breast cancer.
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To identify molecular alterations involved in the initiation and progression
of breast carcinomas in all cell types composing the breast, we gener-
ated Serial Analysis of Gene Expression (SAGE) libraries from purified
epithelial, myoepithelial, endothelial cells, infiltrating leukocytes, and
fibroblasts from normal breast tissue, and in situ and invasive breast car-
cinomas. Based on these SAGE data and follow-up studies using mRNA
in situ hybridization and immunohistochemistry, we determined that dra-
matic gene expression changes occur not only in the epithelial (cancer)
cells, but in various stromal cells as well. We found that the most consis-
tent and dramatic gene expression changes during breast tumor progres-
sion occur in myoepithelial and myofibroblasts cells and the majority of
aberrantly expressed genes encode secreted proteins or cell surface
receptors. Interestingly the receptors for several chemokines upregulated
in myoepithelial cells and/or myofibroblasts are expressed by epithelial
cells. Moreover, we demonstrated that these stromal chemokines
enhance the growth, migration, and invasion of breast cancer cells in
vitro. Based on these data we propose that abnormal paracrine interac-
tions between epithelial and myoepithelial/myofibroblasts cells, mediated
in part by chemokines, may play a role in breast tumorigenesis and the
progression of in situ carcinomas to invasive tumors.
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Breast epithelial stem cells are thought to be the primary targets in the
etiology of breast cancer. Since breast cancers are predominantly
steroid receptor-positive, we tested the hypothesis that normal human
breast epithelial stem cells include a steroid receptor-positive popula-
tion. Based on studies in hematopoietic and other tissues, we isolated a
breast epithelial side population (SP) reported to be enriched in stem
cells. Fluorescence-activated cell sorting analysis indicates that 5% of
breast epithelial cells are SP in nature. Seventy per cent of SP cells lack
markers of myoepithelial (CALLA) and luminal cells (MUC1), suggesting
that they are undifferentiated. This is consistent with reports that breast
stem cells are CALLA–/MUC1– and express cytokeratin (CK) 19. In
three-dimensional matrigel culture, SP (but not non-SP) cells produce
branching structures similar to lobules. These structures comprise at
least two cell populations expressing either CK14 (myoepithelial) or
CK18 (luminal), suggesting that SP cells include a population with the
potential to differentiate. Next, we analysed the relationship between
steroid receptor expression, proliferation and CK19 expression. Results
show that only 10–20% of breast epithelial cells contain receptors for
estrogen and progesterone (ERa and PR), that these cells (70–80%)
are in an intermediate/suprabasal position, are rarely proliferative and
co-express CK19 providing evidence for ERa/PR expression by stem
cells. These data are supported by the finding that SP cells are six times
more likely to express steroid receptors than non-SP cells (60% versus
10%). Another population enriched for stem cells, the label retaining
cells, express the putative stem cell markers Musashi-1 (Msi1) and
p21CIP1, and are also ERa/PR-positive, although Msi1 and p21CIP1
are never co-expressed, suggesting that these molecules have separate
functions in stem cell regulation. The data suggest that ERa/PR-positive
human breast epithelial cells include a stem cell population and thus
steroid receptor-positive breast cancers may arise from steroid receptor-
positive stem cells present in the normal breast epithelium.
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The adult human breast gland consists of a branched system of ducts
and ductules essentially composed of an inner layer of luminal epithelial
cells expressing keratins of simple epithelia and an outer layer of
myoepithelial cells expressing keratins of stratified epithelia and a range
of contractile filaments. With a view to understanding why some breast
carcinomas appear as either basal-like, bimodal or stem cell-derived
and others as strictly luminal epithelial-like, we set out to elucidate
whether a hierarchy of epithelial differentiation could be demonstrated
within the lineages of the human breast gland. For that purpose we
have used primary cultures from reduction mammoplasties, immuno-
magnetic cell sorting and a set of markers for each of the major two lin-
eages. Our initial observations on sorted primary cultures led to the
conclusion that myoepithelial cells were lineage restricted in their differ-
entiation repertoire while a subset of cells within the luminal epithelial
lineage could convert to myoepithelial cells. Next, we included a three-
dimensional reconstituted basement membrane assay in which luminal
epithelial cells essentially formed spherical acinus-like structures while
myoepithelial cells formed larger solid balls. In an effort to enrich for
cells with a broader morphogenic potential we isolated and immortal-
ized a cell type intermediate between luminal and myoepithelial cells,
which could make relatively elaborate terminal duct-like structures and
organize layers of both luminal-like and myoepithelial-like cells. Cur-
rently, we are expanding on our panel of cloned cell lines with normal
cellular equivalents in situ as determined by immunochemical portray-
ing. These cell lines are now being tested for their plasticity in culture
to further approach a tentative hierarchical scheme for breast epithelial
differentiation.
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Although it has been postulated that the epithelial components of the
mammary gland arise through differentiation of a stem cell compart-
ment, the isolation and characterization of these cells have been limited
by the lack of defined cell surface markers and the development of suit-
able in vitro culture systems able to maintain these cells in an undiffer-
entiated state. We have developed an in vitro culture system in which
primary human mammary epithelial cells, isolated from reduction mam-
moplasties, are cultured as ‘mammospheres’ on non-adherent surfaces.
We have demonstrated that mammospheres are highly enriched in
undifferentiated cells capable of both self-renewal as well as differenti-
ation into the three lineages of the mammary gland: myoepithelial cells,
ductal epithelial cells, and alveolar epithelial cells. Affymetrix-based
gene arrays demonstrate a significant overlap between genes
expressed in mammospheres and those previously described in
hematopoietic, neuronal, and embryonic stem cells. Utilizing these
systems, we have found that both leukemia inhibitory factor as well as
NOTCH play a role in cell fate determination. Whereas leukemia
inhibitory factor affects primarily stem cell self-renewal, Notch signaling
affects both self-renewal of stem cells as well as lineage-specific com-
mitment of mammary progenitor cells. We hypothesize that mammary
stem cells or their immediate progeny are targets for transformation
during carcinogenesis. Normal stem cells and carcinoma cells share
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many characteristics, including self-renewal capacity, telomerase
expression, ability to differentiate, resistance to apoptosis, and ability to
home to specific sites. Important events in transformation may involve
disregulation of pathways that control normal stem cell self-renewal,
such as Notch, Wnt, LMO4, PTEN, and BMI1. In addition, the pheno-
typic heterogeneity found in human breast cancers best fits a stem cell
model in which transformed stem or progenitor cells undergo aberrant
differentiation. Using flow cytometry, we have identified a small popula-
tion of cells within primary or metastatic human breast cancers that
bear the cell surface phenotype CD44+CD24–/lowESA+Lineage– that
have properties of tumor stem cells. As few as 200 of these cells are
able to generate tumors in NOD-SCID mice, while the vast majority of
cells in these tumors that lack this phenotype are incapable of tumor
formation, even when tens of thousands of cells are injected. Consis-
tent with a stem cell model, the tumorigenic stem cells generate tumors
that recapitulate the phenotypic heterogeneity found in the original
tumors. Current therapies have been developed by virtue of their ability
to induce tumor regression and may selectively target more differenti-
ated cells in tumors, while leaving the tumor stem cell population intact,
accounting for treatment resistance and relapse. More effective thera-
pies will require the targeting and elimination of the tumor stem cell
population in breast cancer patients.
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Breast cancer is a genetically and clinically heterogeneous disease.
Whether different target cells contribute to this heterogeneity, and
which cell types are most susceptible to oncogenesis is still not well
understood. Identifying mammary cell lineage markers is a prerequisite
for elucidating the function of stem cells in mammary development and
tumorigenesis, and especially for understanding preneoplastic progres-
sion. Our laboratory has used genetically engineered mice coupled with
fluoresence-activated cell sorting analysis and transplantation into the
cleared mammary fat pad, as a model system in which to isolate and
characterize functional mammary progenitors and stem cells. Taking
advantage of approaches similar to those employed to isolate and char-
acterize hematopoietic and epidermal stem cells, we identified a popula-
tion of self-renewing, label retention cells, which excluded Hoechst dye
and were present on fluoresence-activated cell sorting analysis as side-
population (SP) cells. The SP cells and label retention cells represented
approximately 0.5% of mammary epithelial cells in the immature mouse.
DNA microarrays have been employed to determine the gene expres-
sion profiles of these SP cells in comparison with the non-SP popula-
tion. Approximately 75% of the SP cells expressed stem cell antigen-1
(Sca-1). Sca-1 cells have been localized to the terminal end buds of
growing ducts and as few as 1000 Sca-1+ cells were able to generate
mammary gland outgrowths containing luminal, alveolar and myoepithe-
lial cells. In addition, no outgrowths were observed in Sca-1–mammary
epithelial cell transplants. In different genetically engineered mice
mammary tumor models Sca-1 expression levels, as well as several
other putative markers of progenitors, including keratin-6, have dramati-
cally altered expression profiles. For example, Wnt-1 tumors express
these markers and contain at least two populations of tumor cells,
epithelial cells and myoepithelial cells that share secondary mutations
such as loss of p53 and Pten, implying that they arose from a common
progenitor. Mammary tumors arising in transgenic mice expressing β-
catenin and c-myc, downstream components of the canonical Wnt sig-
naling pathway, also contain a significant proportion of myoepithelial
cells as well as cells expressing keratin 6; however, progenitor cell
markers and myoepithelial cells are lacking in mammary tumors from
transgenic mice expressing Neu, H-Ras or polyoma middle T antigen.
Interestingly, K6 expression was also detected in the ductal epithelium
of C/EBPβ null mice, suggesting that germline deletion of this bZIP tran-
scription factor alters mammary epithelial cell fate. These data suggest
that the genetic heterogeneity observed in breast cancer results from
the activation of specific oncogene and/or tumor suppressor-regulated
signaling pathways in specific mammary progenitors. Finally, recent
studies in several other laboratories have identified a comparable popu-
lation of multipotent stem cells in the normal human breast as well as a
population of tumorigenic stem cells in some breast cancers. Under-
standing the differences between normal and cancer stem cells may
provide new therapeutic targets for the treatment of breast cancer.
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Human breast cancer cells are capable of secreting a variety of growth
factors which have autocrine and paracrine functions such as fibroblast
growth factor 2, platelet-derived growth factor and transforming growth
factor beta. Modulations of the synthesis of these paracrine growth
factors by non-toxic therapeutic agents has not been fully investigated.
Sodium phenylacetate (NaPa), a physiological metabolite of phenylala-
nine, has an antiproliferative effect against several human cancer cell
lines. We have previously shown that NaPa exhibits powerful anti-tumor
activity against breast cancer MCF7-ras xenografts in nude mice. More-
over, in this model, we have observed that NaPa can prevent tumor
recurrence after tamoxifen treatment. Although glutamine depletion was
proposed as a mechanism underlying NaPa growth inhibition, protein
prenylation, regulating cellular function of p21/ras, may also be inhib-
ited by NaPa. We showed that NaPa modifies the synthesis of growth
factors secreted by MCF-7 and MCF-7ras tumor cells leading to cell
proliferation inhibitions. This could explain in vitro and in vivo NaPa inhi-
bition of MCF-7ras cells, which secreted higher levels of these growth
factors. It was hypothesized that inhibiting tumor angiogenesis will halt
tumor growth and decrease metastatic potential. Anti-angiogenic
agents targeting the tumor vasculature are expected to block the neo-
vascularization and thereby prevent metastasis. We previously showed
that carbomethyl benzylamide dextran (CMDB7) prevents tumor
growth and tumor angiogenesis by binding to angiogenic growth
factors, thereby preventing them from reaching their receptors on
tumor or stromal cells. We showed that CMDB7 inhibited neovessel
formation within the fibroblast growth factor 2-enriched matrigel in
mice, and its anticancer effect was then tested in a metastatic breast
cancer model. Human MDA-MB435 cells were injected into the
mammary fat pad of nude mice, and breast tumors developed within
1 week; all the mice had lung metastases at 12 weeks. CMDB7 treat-
ment for 10 weeks reduced the incidence of the lung metastases to
12%. Histological analysis showed markedly less tumor neovascular-
ization in the CMDB7-treated mice. We studied the uptake of CMDB7
labeled with 99mTc in MCF-7ras-tumor-bearing mice. The blood clear-
ance of 99mTcCMDB7is rapid and the liver, speen and kidney uptakes
are weak. Our results confirm the non-toxicity of CMDB7 and the use-
fulness of CMDB7 in cancer therapy by targeting breast tumors. Asso-
ciations of CMDB and NaPa show a synergestic antiproliferative effect
on the MCF-7ras cell line. We have synthesized new molecule esters
of CMDB with phenyl-acetic acid. These new molecules, called
NaPaC, are 100-fold more efficient on the in vitro growth of these cells.
NaPaC inhibits the MCF-7ras tumor growth in nude mice 10-fold more
than the parental molecules. Moreover, NaPaC have a strong anti-
angiogenic effect on the MCF-7ras tumors. This anti-angiogenic effect
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is associated with a strong necro-apoptotic effect both in vitro and in
vivo. Taken together, these results show that new cytostatic atoxic mol-
ecules, in associations, can be used as anti-tumoral, anti-angiogenic
and anti-metastatic therapies in breast cancer.
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The use of appropriate mouse models in tumor immunotherapy is a
crucial part of preclinical studies; indeed, without convincing ‘mouse
data’, clinical studies usually do not ensue. However, there are problems
in extrapolating from the mouse to the human; these will be separately
considered for antibody-mediated and cell-mediated immunotherapy.
Antibody-based immunotherapy Monoclonal antibodies can be pas-
sively given to Scid mice bearing human tumors; the monoclonal anti-
bodies may require complement and Fc receptors to mediate their
effect, or act by inhibiting or stimulating signaling, leading to apoptosis.
If complement is crucial, the mouse is not always the best model and
additional complement may need to be provided. In preclinical studies
in cancer, active immunization to produce only antibodies is not often
done; although we have an example where such antibodies were inef-
fective in murine tumor models, but are apparently effective in humans.
Cellular immunity In contrast to passive antibody administration, most
efforts to examine cellular immunity involve direct immunization of mice,
which examines: the antigen; the mode of delivery; and the immuno-
genicity of the antigen, including presentation by both class I and
class II MHC molecules. Human antigens are ‘foreign’ to mice and the
mouse H2 usually presents different peptides than does HLA. To over-
come these problems, transgenic mice and tumors can be used if avail-
able—transgenic for tumor antigens and the MHC. If these are not
available, mouse studies of an antigen are only a guide to immuno-
genicity. Adoptive transfer of human cells (either immune or non-
immune T cells, dendritic cells, etc.) can be used to reconstitute mice,
but this has inherent difficulties, as the infusion is a xenograft. In spite
of all of the problems, useful preclinical data has emerged, and several
examples of different modalities will be presented.
54
Mouse models for pretesting of
immunotherapeutic strategies for cancer patients
JM Burchell, DW Miles, A Mungul, T Plunkett, R Sewell, G Picco,
I Correa, J Taylor-Papadimitriou
Cancer Research UK, Breast Cancer Biology Group, Guy’s Hospital,
London, UK
Breast Cancer Res 2003, 5(Suppl 1):54 (DOI 10.1186/bcr713)
There are two major reasons for using mouse models for preclinical
testing of immunotherapetic strategies before proceeding to clinical
trial. First, the requirements of regulatory authorities for toxicity testing
and, second, the need of the investigator to convince himself/herself
and the grant-giving bodies that proceeding with a clinical trial is scien-
tifically justified. In both cases, the mouse model presents problems
specific to a therapy depending on immune effector cells and their
products. These are particularly evident in evaluating therapies for
cancer patients, where analysis of cellular responses can often be
better evaluated in in vitro studies with human peripheral blood leuko-
cytes. However, where mouse models can show an effect on tumour
growth, they can be extremely useful for evaluating the mechanisms
underlying the effect, as we have found in evaluating tumour rejection
of MUC1 expressing tumours. Moreover, strains carrying transgenes of
human target antigens allow testing for auto-immunity.
Antibody-based therapies Preclinical testing in mouse models has
been successfully translated into the clinic using a humanised version of
the original mouse antibody against the c-erbB2 receptor (Herceptin).
Clinical studies with a humanised MUC1 antibody have been approved
and initiated, even though the data obtained in mouse models were
equivocal. The use of antibodies to deliver toxic agents depends on the
efficacy of delivery of the toxic material: when therapy depends on
delivering high-dose radioactivity, imaging studies in patients can
provide better preclinical testing than the mouse model.
Cell-based therapies Passive delivery of immune effector cells modified
in vitro are in the pipeline for clinical testing. T cells modified with hybrid
receptors (with extracelluar antibody sequences) to target tumour anti-
gens, and dendritic cells loaded with tumour antigens are the focus of
attention. Our own focus is on the MUC1 antigen in both cases. The use
of the mouse model for the T-cell receptor studies may require the devel-
opment of a parallel set of constructs appropriate to the mouse model,
and in vitro studies with human peripheral blood leukocytes may be more
useful. In the case of dendritic cells (DC), the mouse DC are taken from
the bone marrow or spleen, whereas the source of human DC is either
peripheral monocytes stimulated to differentiate into DC or CD34+ cells
isolated from patients treated with granulocyte–macrophage colony-stim-
ulating factor. Nevertheless, much can be gained from the use of mouse
models for evaluating DC-based approaches. Where specific antigens
are being explored, mice transgenic for the antigen are preferred.
Active immunisation against tumour antigens This also includes the
use of DCs loaded with specific antigens or tumour lysates. However,
simpler delivery of the immunogen would be highly preferable since the
good manufacturing practice facilities required for delivery of modified
cells are expensive and sites are limited. DNA-based formulations
provide several advantages. The sequences are easy to manipulate and
production of immunogen can be relatively cheap. The studies in
mouse models to be reported here have led to a small trial using MUC1
cDNA in breast cancer patients, and have allowed characterisation of
important domains in the antigen and of the components of the immune
system important for effective tumour rejection.
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We have established a functional and comprehensive state-of-the-art
expression array technology platform that supports large-scale investi-
gations in human, mouse, rat, zebrafish, and Schizosaccharomyces
pombe systems. Critical to its success is the establishment of a
microarray database with high storage and computational capacity,
development of standardized experimental protocols, novel analytical
approaches, customized analytical tools, and design oligonucleotides
for microarray expansion. The goal is that every expression array experi-
ment performed can be cross-analyzed against another throughout the
history of the institute and with data in the public domain. This data-
dense platform has enabled a far-reaching and comprehensive
genomics approach to the molecular and clinical characterization of
human cancers. We have applied this approach to uncover underlying
transcriptional control cassettes in human breast cancers, and to deci-
pher potential regulatory pathways. Our results suggest that fundamen-
tal mechanisms can be inferred from these genomic observations that
can be readily tested. Some of these examples will be discussed.
56
VelociGene: a high-throughput approach for
functionizing the genome via custom gene mutation
and high-resolution expression analysis in mice
GD Yancopoulos
Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Breast Cancer Res 2003, 5(Suppl 1):56 (DOI 10.1186/bcr715)
Now that the genome has been sequenced, determining gene function
presents the next major challenge. Many scientists agree that the most
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powerful technologies for determining gene function involve genetic
manipulations that knock out, replace, or overexpress gene products in
mice so as to evaluate functional consequences. Unfortunately, even in
the most sophisticated laboratories, such approaches still remain rather
custom and low-throughput. I will describe a new set of technologies that
allow for an unprecedented rate of generation of knockouts, knockins
and transgenics—easily industrializable and scaleable to thousands per
year. These approaches involve rapid manipulation of very large pieces of
DNA (hundreds of kilobases in size), allowing the entire genome to be
spanned by about 25,000 separate pieces of DNA. VelociGene has
enormous flexibility, allowing the production of custom mutations with
nucleotide precision, deletions of very large size, reporter knockins, trans-
genic overexpression, as well as conditional and complex alleles. Geneti-
cally modified mice produced via VelociGene are phenotyped using a
variety of high-throughput approaches, ranging from high-
throughput/high-resolution reporter gene analyses to localize the target
gene with cellular resolution, to four-dimensional transcriptional finger-
printing via microarray. These approaches have identified and validated
multiple targets in therapeutic areas such as obesity and diabetes, arthri-
tis and cartilage growth, muscle atrophy, and angiogenesis and cancer.
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Cancer results from the accumulation of somatic mutations of proto-
oncogenes and/or tumor suppressor genes during carcinogenesis. An
important source of somatic mutations in some animal cancer models
is provirus insertion mutation. Such mutations can arise from either
retrovirus infection or retrotransposition of active proviral elements
present in the germline, and result in the disruption and/or dysregula-
tion of genes at or near sites of new provirus integration. This phenom-
enon serves as the basis for an experimental strategy for identifying
cancer genes, called provirus tagging, in which proviruses act as both
mutagens and tags for the subsequent identification of mutated genes
that participate in carcinogenesis. In the mouse, two retroviruses cause
cancer by this mechanism; mouse mammary tumor virus and murine
leukemia virus. The development of PCR-based methods for efficiently
recovering host/virus junction fragments from new proviral integrants,
as well as the availability of the mouse genome sequence and new
bioinformatics tools, has recently led to a dramatic advance in the
power of this experimental strategy. As a consequence, large-scale
provirus insertion mutation screens are now ongoing in at least three
biotechnology companies and two public research centers. These
screens demonstrate that mouse provirus insertion mutation models
are able to efficiently identify genes involved in human cancer. More-
over, they suggest that an unexpectedly large fraction of the genes in
the mammalian genome can contribute to the process of carcinogen-
esis. Because provirus tagging allows the precise molecular discrimina-
tion between cause and consequence, provirus insertion mutation
models provide a useful new filter for cancer drug target selection.
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Genetic screens can reveal new pathway modifier genes that would be
difficult to uncover using other experimental approaches. The conserva-
tion of biochemical pathways and ability to quickly screen large numbers
of candidate target genes strongly supports the use of model system
genetics. We have carried out large-scale genetic screens in Drosophila
melanogaster,  Caenorhabditis elegans, and cells to identify modifier
genes of cancer-related pathways and phenotypes. Genetic screens
can identify the function of novel genes, and establish functional links
between genes that may have been previously identified, but whose role
in a process was not understood. Invertebrate genetic screens are
carried out in animals or cells with mutations in cancer genes that
produce a measureable phenotype. In Drosophila we typically perform
tissue-specific screens, in the eye or the wing, so that the cancer muta-
tions do not affect viability or fertility of the organism. These sensitized
genetic backgrounds are then screened to identify genes that modify
the visible phenotype. Modifier genes can be identified through reverse
genetic approaches, including transposon insertions and RNA interfer-
ence. The availability of fully sequenced genomes and the use of reverse
genetic tools such as RNA interference enables genetic screens to be
focused on classes of proteins which are amenable to drug discovery,
thus enhancing the efficiency of target identification. Genetic screens
will help build a better understanding of signal transduction pathways
and gene function on a large scale.
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Despite the growing clinical application of monoclonal antibodies as anti-
cancer therapeutics, their ability to destroy targeted tumor cells is sub-
optimal. We have leveraged our Protein Design Automation® technology
to engineer antibodies with greater tumor killing power by augmenting
the capacity of the Fc region to interact with the Fc gamma receptors
(FcγRs) that mediate cytotoxic effector functions. A panel of Fc variants
has been generated that display substantial enhancements over existing
variants in both in vitro Fc/FcγR binding assays and cell-based ADCC
assays. Our most promising candidates have been validated in the
context of three approved anti-cancer antibodies, and characterized with
regard to their specificity for activation versus inhibitory receptors, and
their affinity for clinically relevant polymorphic forms of FcγRIIIa.
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Applied Genomics Inc., through its collaboration with investigators at
Stanford University, has targeted the production of over 650 polyclonal,
affinity-purified, anti-peptide antibody reagents to candidate genes
thought to distinguish biologically distinct subclasses of carcinoma. We
have screened and validated these reagents by performing immunohisto-
chemistry on proprietary tissue arrays constructed in-house using over
300 independent tumor samples from each of breast, lung, and colon
carcinoma. We have used this database to identify proprietary antibody
panels useful for distinguishing the diversity of cancer cases within tissue
types and similarities between subclasses derived from different tissues.
Individual reagents within these antibody panels are beginning to reveal
staining patterns that distinguish novel subtypes of cells in normal
tissues, and subclasses of tumors that transcend tissue origins. We are
using our subclassification panels in collaboration with clinical trials
groups and pharmaceutical companies to identify subclasses of patients
that respond to existing therapeutics and novel therapeutics that are in
development. The goal of this work is to identify biomarkers for patient
selection both in late-phase clinical trials and for marketed therapeutics.
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Scientists and clinicians are familiar with Affymetrix Genechip™ arrays
being utilized predominantly in the areas of basic research, target dis-
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covery, and target validation. Recently, however, studies are being con-
ducted and published using this research use only platform in clinical
research, including phase II and phase III clinical trials. During this pre-
sentation, two breast cancer studies will be reviewed. One study uti-
lizes gene expression profiling for predicting therapeutic response to
docetaxel [1]. The other study, loss of heterozygosity in breast cancer,
utilizes our new DNA analysis array for mapping over 10,000 single
nucleotide polymorphisms in the human genome.
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The primary therapeutic goal for patients with locally recurrent, locally
advanced, or metastatic breast cancer is retarding the progression of
cancer for as long as possible, while minimizing side effects and main-
taining good quality of life. The majority of breast cancers have nuclear
receptors for estrogen (ER) and/or progesterone (PR) and utilize estro-
gen as a major growth factor. Antagonizing estrogen to control tumor
growth has been achieved in two ways: by competing for the binding
site of the estrogen receptor with anti-estrogens (SERMS) or by
removing estrogen by inhibiting its synthesis with aromatase (estrogen
synthetase) inhibitors (AIs). Cancer cells develop resistance to SERMS
such as tamoxifen (Nolvadex®) or toremifene (Fareston®) by increasing
uptake of estrogens from plasma, by developing hypersensitivity to the
residual level of ER stimulation and by increasing levels of estrogen
synthesizing enzymes, such as aromatase, within the tumor cells as
much as 3–10 fold. High in-situ, intra- and peri-tumoral estrogen levels
may displace the SERM and cause clinical progression of the disease.
In contrast resistance to AI therapy may also develop by causing hyper-
sensitivity to residual and exogenous estrogens. Hence it has been
hypothesized that a combination of a SERM and an AI (total estrogen
blockade) might be the optimal way to treat hormone dependent breast
cancer and prevent the emergence of resistance. Combining tamoxifen
(SERM) with an AI (anastrozole) was one of three arms of the Phase 3
adjuvant ATAC study comparing tamoxifen to anastrozole and the com-
bination. Interestingly the combination arm performed worst of all, the
hypothesis being that in the low estrogenic environment created by the
AI, tamoxifen exaggerates its known partial estrogenic signal. It has
been hypothesized that if a SERM with less inherent estrogenicity than
tamoxifen were combined with an AI the therapy would be more suc-
cessful. Similar to letrozole and tamoxifen combined in another trial, a
27% reduction in plasma levels of anastrozole was also detected. Bio-
Medicines is currently testing that hypothesis in a clinical Phase 3 trial
combining the experimental and currently unapproved AI atamestane
and the approved SERM toremifene and comparing that combination
to the approved AI letrozole. Toremifene is clinically equi-effective
against tamoxifen in treatment naïve patients, but is 40-fold less estro-
genic in a low estrogen environment in preclinical models. Atamestane
is a steroidal AI, which has shown a median time to progression of 8
months, with 10% of the patients progression-free at 36 months, in
tamoxifen-resistant patients. It is well tolerated and may have advan-
tages over the non-steroidal AI’s in terms of efficacy and toxicity.
Atamestane also does not interact pharmacologically with the
toremifene. The control arm is letrozole, currently the most effective
single agent endocrine therapy for postmenopausal women. Patients
eligible for our study are required to have positive receptor status, have
measurable tumor lesions and to have received the last dose of adju-
vant hormonal therapy at least 12 months prior to enrollment. Our trial
strategy is thus similar to the total androgen blockade approach to
prostate cancer where this approach has been successful.
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CTLA-4 is a negative regulator of T cell activity. Antibodies to CTLA-4
have been shown to directly activate anti-tumor responses in a several
syngeneic murine models. For less immunogenic murine tumors, anti-
CTLA-4 treatment has anti-tumor activity when combined with vaccines
or other therapeutic regimens. In order to explore the use of CTLA-4
blockade in human immunotherapy, we have developed and character-
ized an antibody to human CTLA-4 (MDX-010), derived from HuMAb
mice, which blocks the binding of CTLA-4 to B7 ligands. MDX-010
was able to inhibit the growth of tumors in mice transgenic for human
CTLA-4. Vaccination experiments and multiple dosing in primates were
used to further define the activity and safety profiles of MDX-010.
Several human clinical trials using MDX-010 have been completed and
multiple trials are in progress; the clinical experience in these trials will
be summarized.
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